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A B S T R A C T
Background
Insulin requirements may change during pregnancy, and the optimal treatment for pre-existing diabetes is unclear. There are several
insulin regimens (e.g. via syringe, pen) and types of insulin (e.g. fast-acting insulin, human insulin).
Objectives
To assess the effects of different insulin types and different insulin regimens in pregnant women with pre-existing type 1 or type 2 diabetes.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 October 2016), ClinicalTrials.gov (17 October 2016), the
WHO International Clinical Trials Registry Platform (ICTRP; 17 October 2016), and the reference lists of retrieved studies.
Selection criteria
We included randomised controlled trials (RCTs) that compared different insulin types and regimens in pregnant women with pre-existing
diabetes.
We had planned to include cluster-RCTs, but none were identified. We excluded quasi-randomised controlled trials and cross-over trials.
We included studies published in abstract form and contacted the authors for further details when applicable. Conference abstracts were
superseded by full publications.
Data collection and analysis
Two review authors independently assessed trials for inclusion, conducted data extraction, assessed risk of bias, and checked for accuracy.
We assessed the quality of the evidence using the GRADE approach.
Main results
The findings in this review were based on very low-quality evidence, from single, small sample sized trial estimates, with wide confidence
intervals (CI), some of which crossed the line of no effect; many of the prespecified outcomes were not reported. Therefore, they should be
interpreted with caution. We included five trials that included 554 women and babies (four open-label, multi-centre, two-arm trials; one
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single centre, four-arm RCT). All five trials were at a high or unclear risk of bias due to lack of blinding, unclear methods of randomisation,
and selective reporting of outcomes. Pooling of data from the trials was not possible, as each trial looked at a different comparison.
1. One trial (N = 33 women) compared Lispro insulin with regular insulin and provided very low-quality evidence for the outcomes. There
were seven episodes of pre-eclampsia in the Lispro group and nine in the regular insulin group, with no clear difference between the two
groups (risk ratio (RR) 0.68, 95% CI 0.35 to 1.30). There were five caesarean sections in the Lispro group and nine in the regular insulin group,
with no clear difference between the two groups (RR 0.59, 95% CI 0.25 to 1.39). There were no cases of fetal anomaly in the Lispro group
and one in the regular insulin group, with no clear difference between the groups (RR 0.35, 95% CI 0.02 to 8.08). Macrosomia, perinatal
deaths, episodes of birth trauma including shoulder dystocia, nerve palsy, and fracture, and the composite outcome measure of neonatal
morbidity were not reported.
2. One trial (N = 42 women) compared human insulin to animal insulin, and provided very low-quality evidence for the outcomes. There
were no cases of macrosomia in the human insulin group and two in the animal insulin group, with no clear difference between the groups
(RR 0.22, 95% CI 0.01 to 4.30). Perinatal death, pre-eclampsia, caesarean section, fetal anomaly, birth trauma including shoulder dystocia,
nerve palsy and fracture and the composite outcome measure of neonatal morbidity were not reported.
3. One trial (N = 93 women) compared pre-mixed insulin (70 NPH/30 REG) to self-mixed, split-dose insulin and provided very low-quality
evidence to support the outcomes. Two cases of macrosomia were reported in the pre-mixed insulin group and four in the self-mixed
insulin group, with no clear difference between the two groups (RR 0.49, 95% CI 0.09 to 2.54). There were seven cases of caesarean section
(for cephalo-pelvic disproportion) in the pre-mixed insulin group and 12 in the self-mixed insulin group, with no clear difference between
groups (RR 0.57, 95% CI 0.25 to 1.32). Perinatal death, pre-eclampsia, fetal anomaly, birth trauma including shoulder dystocia, nerve palsy,
or fracture and the composite outcome measure of neonatal morbidity were not reported.
4. In the same trial (N = 93 women), insulin injected with a Novolin pen was compared to insulin injected with a conventional needle
(syringe), which provided very low-quality evidence to support the outcomes. There was one case of macrosomia in the pen group and five
in the needle group, with no clear difference between the different insulin regimens (RR 0.21, 95% CI 0.03 to 1.76). There were five deliveries
by caesarean section in the pen group compared with 14 in the needle group; women were less likely to deliver via caesarean section when
insulin was injected with a pen compared to a conventional needle (RR 0.38, 95% CI 0.15 to 0.97). Perinatal death, pre-eclampsia, fetal
anomaly, birth trauma including shoulder dystocia, nerve palsy, or fracture, and the composite outcome measure of neonatal morbidity
were not reported.
5. One trial (N = 223 women) comparing insulin Aspart with human insulin reported none of the review's primary outcomes: macrosomia,
perinatal death, pre-eclampsia, caesarean section, fetal anomaly, birth trauma including shoulder dystocia. nerve palsy, or fracture, or
the composite outcome measure of neonatal morbidity.
6. One trial (N = 162 women) compared insulin Detemir with NPH insulin, and supported the outcomes with very low-quality evidence.
There were three cases of major fetal anomalies in the insulin Detemir group and one in the NPH insulin group, with no clear difference
between the groups (RR 3.15, 95% CI 0.33 to 29.67). Macrosomia, perinatal death, pre-eclampsia, caesarean section, birth trauma including
shoulder dystocia, nerve palsy, or fracture and the composite outcome of neonatal morbidity were not reported.
Authors' conclusions
With limited evidence and no meta-analyses, as each trial looked at a different comparison, no firm conclusions could be made about
different insulin types and regimens in pregnant women with pre-existing type 1 or 2 diabetes. Further research is warranted to determine
who has an increased risk of adverse pregnancy outcome. This would include larger trials, incorporating adequate randomisation and
blinding, and key outcomes that include macrosomia, pregnancy loss, pre-eclampsia, caesarean section, fetal anomalies, and birth trau-
ma.
P L A I N   L A N G U A G E   S U M M A R Y
What is the best insulin type and regimen for pregnant women with pre-existing diabetes?
What is the issue?
The insulin needs of pregnant women with type 1 or 2 diabetes change during pregnancy. Insulin is available in many forms, which affect
how often and when the insulin is given. These forms vary in the time needed before the insulin has its effect, how long the effect may last,
and whether it is made from animals or humans, which may be important personally or culturally. This review looked at the safest and
most effective types and ways of giving insulin during pregnancy.
Why is this important?
Women with type 1 or 2 diabetes are at increased risk of complications during pregnancy and birth. They are more likely to experience
pregnancy loss (stillbirth, miscarriage), high blood pressure and pre-eclampsia (high blood pressure associated with swelling and protein
in the urine), and have large babies (called macrosomia, when the baby is 4 kg or more at birth) that result in injury to the mother or baby.
The likelihood of having a caesarean is increased. Mothers and babies may have complications related to managing blood glucose levels.
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The baby is more likely to become overweight and develop type 2 diabetes. We wanted to find out the best type of insulin and regimen
to use during pregnancy.
What evidence did we find?
We found five randomised trials (N = 554 women and 554 babies) in October 2016. Each trial looked at different insulin types and ways
of giving the insulin. Different outcomes were looked at in each trial. One trial did not include any of the review's main outcomes. All five
trials were small, and at a high or unclear risk of bias because of limitations in how the trials were conducted. The quality of the evidence
was very low.
When rapid-acting human insulin (Lispro) was compared to regular insulin (N = 33), investigators found no clear differences between the
groups for pre-eclampsia, abnormalities in the baby, or the need for a caesarean. Macrosomia, perinatal death, birth trauma including
shoulder dystocia, nerve palsy, and fracture, and the composite measure of neonatal morbidity were not reported.
One trial (N = 43) that compared human insulin to animal insulin did not show any clear difference in the number of babies with macroso-
mia. Perinatal death, pre-eclampsia, caesarean section, fetal anomaly, birth trauma including shoulder dystocia, nerve palsy, and fracture,
and the composite measure of neonatal morbidity were not reported.
One trial (N = 93) found no clear differences between pre-mixed and self-mixed insulin groups in the number of babies with macrosomia,
and the number of women who had a caesarean section. This trial also compared insulin injected with a pen and a needle (syringe). Women
in the insulin pen group were less likely to have a caesarean section, although the number of macrosomic babies was not clearly different.
Perinatal death, pre-eclampsia, fetal anomaly, birth trauma including shoulder dystocia, nerve palsy, and fracture, and the composite
measure of neonatal morbidity were not reported.
One trial (N = 223) comparing insulin Aspart to human insulin did not include any of the review's primary outcomes (macrosomia, perinatal
death, pre-eclampsia, caesarean section, fetal anomaly, birth trauma including shoulder dystocia, nerve palsy, and fracture, or the com-
posite measure of neonatal morbidity).
One trial (N = 162), which compared long-acting insulin Detemir with the intermediate-acting neutral protamine Hagedorn (NPH) insulin
found the number of fetal abnormalities was not clearly different between groups. The trial did not measure macrosomia, perinatal death,
pre-eclampsia, caesarean section, birth trauma including shoulder dystocia, nerve palsy, and fracture, or the composite outcome measure
of neonatal morbidity.
What does this mean?
The trials did not provide sufficient evidence to identify clear differences between the various insulin types and regimens. Each study
looked at a different type of insulin or regimen, so we could not combine the results. The studies were small, with overall high risk of bias.
Therefore, we could not conclude which insulin type or regimen was best for pregnant women with pre-existing diabetes. More research
is needed with larger groups of women, better reporting of how the trials were conducted, and more reported outcomes.
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Summary of findings for the main comparison.   Lispro versus regular insulin (Dierent insulin types within similar insulin regimens)
Lispro versus regular insulin (Different insulin types within similar insulin regimens)
Patient or population: pregnant women with pre-existing diabetes
Setting: four centres in Sweden. The Departments of Obstetrics and Gynaecology in Huddinge Hospital, Karolinska Hospital, Södersjukhuset in Stockholm, and Örebro Re-
gional Hospital
Intervention: Lispro
Comparison: regular insulin
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
regular in-
sulin
Risk with
Lispro
Relative effect
(95% CI)
№ of participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Macrosomia       (0 studies) Not reported  
Study populationPerinatal death
0 per 1000 0 per 1000
(0 to 0)
not estimable 33
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1, 2, 3
 
Study populationPre-eclampsia
647 per 1000 440 per 1000
(226 to 841)
RR 0.68
(0.35 to 1.30)
33
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1, 3,
4, 5
 
Study populationCaesarean section
529 per 1000 312 per 1000
(132 to 736)
RR 0.59
(0.25 to 1.39)
33
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1, 3,
4, 5
 
Study populationFetal anomaly
59 per 1000 21 per 1000
(1 to 475)
RR 0.35
(0.02 to 8.08)
33
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1, 3,
4, 5
 
Study populationBirth trauma, including shoulder dysto-
cia, nerve palsy, and fracture
0 per 1000 0 per 1000
Not estimable 33
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1, 2, 3
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(0 to 0)
Composite outcome measure of neona-
tal morbidity
      (0 studies) Not reported  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 High or unclear risk of bias for allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome
reporting, and other biases
2 Small sample size and no events
3 One study with design limitations
4 Very wide 95% confidence intervals crossing the line of no effect
5 Small sample size with few events
 
 
Summary of findings 2.   Human insulin versus animal insulin (Dierent insulin types within similar insulin regimens)
Human insulin versus animal insulin (Different insulin types within similar insulin regimens)
Patient or population: pregnant women with pre-existing diabetes
Setting: The Children's Hospital of San Francisco and Cornell University Medical College, New York
Intervention: human insulin (recombinant deoxyribonucleic acid - Humulin)
Comparison: animal insulin
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with ani-
mal insulin
Risk with hu-
man insulin
(Humulin)
Relative effect
(95% CI)
№ of participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study populationMacrosomia
91 per 1000 20 per 1000
RR 0.22
(0.01 to 4.30)
42
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2 3 4
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(1 to 391)
Perinatal death       (0 studies) Not reported  
Pre-eclampsia       (0 studies) Not reported  
Caesarean section       (0 studies) Not reported  
Fetal anomaly       (0 studies) Not reported  
Birth trauma including shoulder
dystocia, nerve palsy, and fracture
      (0 studies) Not reported  
Composite outcome measure of
neonatal morbidity
      (0 studies) Not reported  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Risk of bias was high or unclear for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete
outcome data, and selective outcome reporting
2 One study with serious design limitations including lack of blinding for allocation concealment
3 Very wide 95% confidence intervals crossing the line of no effect
4 Small sample size and few events
 
 
Summary of findings 3.   Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Dierent insulin regimens with similar insulin types
used within the regimen)
Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Different insulin regimens with similar insulin types used within the regimen)
Patient or population: pregnant women with pre-existing diabetes
Setting: University of Mississippi Medical Centre, USA
Intervention: pre-mixed insulin (70 NPH/30 REG)
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Comparison: self-mixed split dose insulin
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
self-mixed
split dose in-
sulin
Risk with
pre-mixed
insulin (70
NPH/30 REG)
Relative effect
(95% CI)
№ of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Study populationMacrosomia
87 per 1000 43 per 1000
(8 to 221)
RR 0.49
(0.09 to 2.54)
93
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1, 2, 3
 
Perinatal death       (0 studies) Not reported  
Pre-eclampsia       (0 studies) Not reported  
Study populationCaesarean section 4
261 per 1000 149 per 1000
(65 to 344)
RR 0.57
(0.25 to 1.32)
93
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2 3
 
Fetal anomaly       (0 studies) Not reported  
Birth trauma including shoulder
dystocia, nerve palsy, or fracture
      (0 studies) Not reported  
Composite outcome measure of
neonatal morbidity
      (0 studies) Not reported  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
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1 Very wide 95% confidence intervals crossing the line of no effect
2 Small sample size and few events
3 One study with serious design limitations
4 Caesarean section for cephalo-pelvic disproportion
 
 
Summary of findings 4.   Insulin injected with a Novolin pen versus insulin injected with a needle or syringe (Dierent insulin regimens with similar
insulin types used within the regimen)
Insulin injected with a Novolin pen versus insulin injected with a needle or syringe (Different insulin regimens with similar insulin types used within the regimen)
Patient or population: pregnant women with pre-existing diabetes
Setting: University of Mississippi Medical Centre, USA
Intervention: insulin injected with a Novolin pen
Comparison: insulin injected with a needle or syringe
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with in-
sulin injected
with a needle
or syringe
Risk with in-
sulin inject-
ed with a No-
volin pen
Relative effect
(95% CI)
№ of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Study populationMacrosomia
104 per 1000 22 per 1000
(3 to 183)
RR 0.21
(0.03 to 1.76)
93
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1, 2 ,3
 
Perinatal death       (0 studies) Not reported  
Pre-eclampsia       (0 studies) Not reported  
Study populationCaesarean section 4
292 per 1000 111 per 1000
(44 to 283)
RR 0.38
(0.15 to 0.97)
93
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1, 2, 3
 
Fetal anomaly       (0 studies) Not reported  
Birth trauma including shoulder
dystocia, nerve palsy, or fracture
      (0 studies) Not reported  
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Composite outcome measure of
neonatal morbidity
      (0 studies) Not reported  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Very wide 95% confidence intervals crossing the line of no effect
2 Small sample size with few events
3 One study with serious design limitations
4 Caesarean section for cephalo-pelvic disproportion
 
 
Summary of findings 5.   Insulin Aspart (+ NPH) compared to human insulin (+ NPH insulin) for pregnant women with pre-existing diabetes (Dierent
insulin types within similar insulin regimens)
Insulin Aspart (+ NPH) compared to human insulin (+ NPH) for pregnant women with pre-existing diabetes (Different insulin types within similar insulin regimens)
Patient or population: pregnant women with pre-existing diabetes
Setting: 63 different sites in 18 countries
Intervention: insulin Aspart (+ NPH insulin)
Comparison: human insulin (+ NPH insulin)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with hu-
man insulin
(+ NPH)
Risk with in-
sulin Aspart
(+ NPH)
Relative effect
(95% CI)
№ of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Macrosomia - - - - - Not reported
Perinatal death - - - - - Not reported
Pre-eclampsia - - - - - Not reported
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Caesarean section - - - - - Not reported
Fetal anomaly - - - - - Not reported
Birth trauma including shoul-
der dystocia, nerve palsy and
fracture
- - - - - Not reported
Composite outcome measure
of neonatal morbidity
- - - - - Not reported
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
 
 
Summary of findings 6.   Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin Aspart (Dierent insulin types within similar
insulin regimens)
Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin Aspart (Different insulin types within similar insulin regimens)
Patient or population: pregnant women with pre-existing diabetes
Setting: 79 sites in 17 countries, mainly within Europe
Intervention: insulin Detemir (+ Aspart)
Comparison: NPH (+ Aspart)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
NPH (+ As-
part)
Risk with in-
sulin Detemir
(+ Aspart)
Relative effect
(95% CI)
№ of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Macrosomia       (0 studies) Not reported  
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Perinatal death       (0 studies) Not reported  
Pre-eclampsia       (0 studies) Not reported  
Caesarean section       (0 studies) Not reported  
Study populationFetal anomaly (major) 1
12 per 1000 38 per 1000
(4 to 357)
RR 3.15
(0.33 to 29.67)
162
(1 RCT)
⊕⊝⊝⊝
VERY LOW 2, 3, 4, 5
 
Birth trauma including
shoulder dystocia, nerve
palsy, or fracture
      (0 studies) Not reported  
Composite outcome mea-
sure of neonatal morbidity
      (0 studies) Not reported  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Assessed by an expert who was blinded to the outcome
2 One study with design limitations
3 Very wide 95% confidence intervals crossing the line of no effect
4 Large effect estimate
5 Small sample size with few events
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B A C K G R O U N D
Description of the condition
Diabetes mellitus
The term (DM) describes a metabolic disorder of multiple aetiology,
characterised by chronic hyperglycaemia with disturbances of car-
bohydrate, fat, and protein metabolism that results from defects
in insulin secretion, insulin action, or both (WHO 1999). Diabetes
mellitus can occur during pregnancy in two forms, pre-gestation-
al diabetes mellitus and gestational diabetes mellitus (GDM; Dafla-
purkar 2014). Pre-gestational diabetes refers to type 1 or type 2 di-
abetes and is diagnosed before conception. Historically, type 1 dia-
betes was considered a disorder of children and adolescents, gen-
erally occurring early in life, with a sudden onset of insulin deficien-
cy. Age at onset of diagnosis is no longer a restricting factor (Atkin-
son 2014). Type 2 diabetes has been largely attributed to increas-
ing obesity and socioeconomic status (Kothari 2014; Morton 2014).
Gestational diabetes mellitus is a carbohydrate intolerance that re-
sults in hyperglycaemia (an excess of sugar in the blood) of variable
severity, with onset or first recognition during pregnancy. It does
not exclude the possibility that the glucose intolerance may ante-
date pregnancy but has been previously unrecognised. The defin-
ition applies regardless of whether or not insulin is used for treat-
ment, or the condition persists after pregnancy (WHO 1999). This
review will only include women with pre-existing DM (type 1 or 2).
Pathophysiology
Diabetes mellitus can be defined as abnormal glucose metabolism
due to lack of, or relatively low, insulin production. It results in el-
evation of blood glucose levels with effects on all the vital organs.
Type 1 DM describes a condition in which the pancreas is no longer
able to produce sufficient insulin due to the destruction of the be-
ta cells by an autoimmune process. According to the World Health
Organization (WHO) definition, type 1 DM "includes those cases at-
tributable to an autoimmune process, as well as those with be-
ta-cell destruction, which are prone to ketoacidosis for which nei-
ther an aetiology nor a pathogenesis is known (idiopathic). It does
not include those forms of beta-cell destruction or failure to which
specific causes can be assigned (e.g. cystic fibrosis, mitochondrial
defects, etc.)" (WHO 1999). Type 2 DM includes the common ma-
jor form of diabetes that results from defects in insulin secretion,
almost always with a major contribution from insulin resistance
(Nolan 2011; WHO 1999).
Epidemiology
Diabetes mellitus is increasing globally and the number of adults
with diabetes has more than doubled over nearly three decades,
driven by both population growth and ageing, as well as the in-
creasing levels of overweight and obesity (Danaei 2011). In Canada,
the percentage of pregnant women with pre-existing DM rose from
0.7% to 1.5% between 1996 and 2010 (Feig 2014). Similar increasing
trends of DM in pregnant women have been reported in the Unit-
ed States (Albrecht 2010; Lawrence 2008), and the United Kingdom
(Bell 2008). Type 2 diabetes accounts for approximately 85% to 90%
of all cases of diabetes in European countries, and is the driving
force behind increasing diabetes rates (Wass 2011). Furthermore,
DM is the most common pre-existing medical condition complicat-
ing pregnancy; the outcome for diabetic pregnancy remains poor,
despite improvements in care (Kumareswaran 2013). Pre-existing
DM complicates approximately 1.3% of pregnancies, one-third of
these are type 1 DM, the remaining two thirds are type 2 DM (Bell
2008; Feghali 2012).
Risk factors associated with DM
Although the exact causes of type 1 DM are unknown, factors that
may signal an increased risk include the following (Daneman 2006).
• Family history (risk increases if a parent or sibling has type 1 DM).• Environmental factors (circumstances such as exposure to a vi-
ral illness likely play some role in type 1 DM).• The presence of damaging immune system cells (autoantibod-
ies). Sometimes family members of people with type 1 DM are
tested for the presence of diabetes autoantibodies. The pres-
ence of these antibodies is associated with an increased risk of
developing type 1 DM, but not everyone who has these autoan-
tibodies develops DM.• Dietary factors (including low vitamin D consumption, early ex-
posure to cow's milk or cow's milk formula, and exposure to ce-
reals before four months of age. None of these factors has been
shown to directly cause type 1 DM).• Geography. Certain countries, such as Finland and Sweden,
have higher rates of type 1 DM.
It is not fully understood why some people develop type 2 DM and
others do not. However, certain factors increase the risk, including
the following (Kim 2002).
• Weight (the more fatty tissue present, the more resistant cells
become to insulin).• Inactivity (the less active a person is, the greater the risk. Physi-
cal activity helps control weight, uses up glucose as energy and
makes cells more sensitive to insulin).• Family history (risk increases if a parent or sibling has type 2 DM).• Race (certain races — including blacks, Hispanics, American In-
dians, and Asian-Americans are at higher risk, although it is not
clear why).• Age (risk increases as you get older, perhaps due to less exercise,
lost muscle mass, and weight gain as you age, however, type 2
DM is also increasing dramatically among children, adolescents,
and younger adults).• GDM (if a woman developed gestational diabetes when preg-
nant, her risk of developing prediabetes and type 2 DM later in-
creases. If a woman gave birth to a baby weighing more than
nine pounds (four kilograms), the risk of type 2 DM also increas-
es).• Polycystic ovary syndrome (a common condition characterised
by irregular menstrual periods, excess hair growth, and obesity)
increases the risk of DM).• High blood pressure, over 140/90 millimetres of mercury
(mmHg), is linked to an increased risk of type 2 DM.• Abnormal cholesterol and triglyceride levels (low levels of high-
density lipoprotein (HDL), or 'good' cholesterol, result in an in-
creased risk of type 2 DM, as does a high level of triglycerides).• Gender (higher prevalence of diabetes among men, and men
develop diabetes at lower body mass index (BMI) levels than
women).
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Possible complications in pregnant women with DM and their
ospring
Diabetes in pregnancy is associated with risks to the woman and
the developing fetus (Adam 2014; Ali 2011; Bartz 2012; Billionnet
2014; Carter 2012; Feig 2014; Fraser 2014; Holman 2014; Kapoor
2007; Krane 2014; Morken 2014; Øverland 2014; Ryu 2014; Tennant
2014; Yessoufou 2011).
• Increased risk of complications of DM, including ketoacidosis,
hypoglycaemia, retinopathy, and nephropathy.• Increased risk of obstetric complications, including preg-
nancy-induced hypertension, thromboembolism, obstructed
labour, polyhydramnios, maternal infection, caesarean section,
pre-eclampsia, and preterm labour.• Increased risk of fetal and neonatal complications, including
miscarriage, stillbirth, congenital malformations, macrosomia,
birth injury, perinatal mortality, postnatal adaptation problems
(e.g. hypoglycaemia (reduced levels of blood sugar)), fetal dis-
tress, respiratory distress syndrome, and jaundice.• Long-term outcomes of offspring born to diabetic mothers in-
clude an increased risk of obesity, impaired cognitive ability,
and type 2 diabetes.
Management of DM in pregnancy
The management of pregnant women with type 1 diabetes involves
the use of insulin to control blood glucose levels. During pregnancy,
a woman's insulin requirements may increase by up to three to four
times her pre-pregnancy dose; insulin management is tailored to
the individual (McCance 2010). In type 2 diabetes, lifestyle changes,
including a healthy diet and regular exercise, are the first line of
treatment, with the use of oral hypoglycaemic agents or insulin
to lower blood glucose, if necessary. Therefore, the management
of diabetes in pregnancy is complex, and includes a combination
of preconception care, glycaemic control and monitoring, obtain-
ing target blood glucose levels, monitoring glycated haemoglobin
(HbA1c) levels, retinal assessment, carefully tailored insulin treat-
ment, ketone testing, renal assessment, monitoring fetal growth
and well-being, and postnatal care (Balaji 2011; Ballas 2012; NICE
2015).
Description of the intervention
Insulin is a hormone made naturally in the body by pancreatic beta
cells. This hormone controls the level of glucose in the blood. There
are different types of insulin available, which are classified accord-
ing to how quickly and for how long they work on various parts of
the body. There are also many different methods of administering
insulin, referred to as 'regimens'. This review focuses on the effica-
cy and safety of different insulin types and the various regimens of
insulin delivery during pregnancy. The appropriate insulin type and
regimen for each woman will depend on a number of factors, in-
cluding the type of diabetes, previous control, age, dexterity, eye-
sight, and personal and cultural preferences (Greuter 2012).
Types of insulin
Insulins can be classified into various types, according to their du-
ration of action (Mooradian 2006; NICE 2015).
• Short-acting insulin (e.g. Humulin, Novolin): should be injected
15 to 30 minutes before a meal, to cover the rise in blood glucose
levels that occurs after eating. This insulin has a peak action of
two to six hours, and can last for up to eight hours.• Rapid-acting insulin analogues (e.g. Aspart, Lispro): genetical-
ly engineered analogues of human insulin, which work like in-
sulin that is normally produced with a meal. Onset of action
is approximately 15 minutes, peaking at one hour, and lasting
three to four hours. They can be injected shortly before, during,
or immediately after meals.• Long-acting insulin analogues (e.g. Detemir, Glargine): geneti-
cally modified analogues, with an onset of action at one to three
hours; they plateau and last for 20 to 24 hours. Generally used
once- or twice-daily to produce a constant flow of insulin, they
are physiologically similar to normal endogenous basal insulin
secretion.• Intermediate-acting (medium-acting) insulins (e.g. isophane
or neutral protamine Hagedorn (NPH)): these have an onset of
action of two to four hours, peak at six to seven hours, and last 20
hours. Isophane insulin is ideal for twice-daily insulin regimens,
and can be mixed with soluble insulin.• Mixed insulin (Biphasic insulin): a combination of medium-act-
ing and rapid-acting or short-acting insulin.• Mixed analogue: a combination of medium-acting insulin and
rapid-acting analogue.
Insulin regimens
In this review, the term 'insulin regimen' refers to an overall strategy
for insulin delivery that typically specifies:
• the frequency of insulin injections (e.g. once, twice daily);• the type of insulin administered (e.g. intermediate-, long-act-
ing); and• the timing of insulin injections (e.g. bedtime, before breakfast).
The main insulin regimens are as follows.
Once-daily regimen• Long- or intermediate-acting insulin administered at bedtime in
people with type 2 diabetes only.• It may be used in addition to oral hypoglycaemic agents.• This regimen is generally used when starting insulin in type 2 di-
abetes and when it is necessary for others to administer the in-
jections.
Twice-daily regimen• A biphasic insulin is injected twice a day (before breakfast and
before the evening meal).• Assumes three meals a day are consumed, and peak action
varies according to the amount of soluble insulin in the mixture.• Optimal glycaemic control can be difficult to maintain, resulting
in hypoglycaemic episodes.• Additional snacks are often required between meals, given the
overlap between short-acting and long-acting insulin.
Basal-bolus regimen• Intermediate- or long-acting insulin is administered at bedtime
to cover overnight insulin requirements, and is combined with
rapid- or short-acting insulin injections to cover mealtimes.
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When intensified insulin therapy is used to provide optimal gly-
caemic control, this is the most commonly used insulin regimen,
and is also known as multiple daily injections (MDI).
Continuous subcutaneous insulin infusion, or insulin pump
therapy• Continuous subcutaneous insulin infusion (CSII) or insulin pump
therapy is when basal insulin is given via a catheter, supplied
from a syringe reservoir worn under clothing.• The woman can activate pre-meal boluses, and the pump can
be deactivated for up to one hour to facilitate activities, such as
swimming.• The pump can be pre-programmed, and as a result, the insulin
absorption is more predictable than multiple daily injections.• CSII provides some advantages over multiple daily injections in
type 1 diabetes for children and adults who have recurrent hy-
poglycaemia, delayed meals, or pre-breakfast hyperglycaemia.
Continuous subcutaneous insulin infusion regimens have been
covered extensively in two previous Cochrane reviews, and will not
be included in the current review (Farrar 2016; Misso 2010).
Insulin dosage
Insulin dosage should be individualised to achieve and maintain a
target blood glucose level, and is determined by various factors,
including body weight, body fat, physical activity, insulin sensitivi-
ty, blood glucose levels, and target blood glucose. Insulin dosage
is usually based on body weight (insulin unit per kilogram of body
weight). One international unit of insulin (1 IU) is defined as the 'bio-
logical equivalent' of 34.7 µg of pure crystalline insulin (Beals 2013).
Daily insulin requirements may be higher during illness, stress,
pregnancy, in obese people, trauma, during concurrent use with
medications having hyperglycaemic effects, or after surgery, and
may be lower with exercise, weight loss, calorie restricted diets,
or during concurrent use of medications having hypoglycaemic ef-
fects. Total daily doses should not be adjusted by more than 10%
increments. Supplemental doses may be prescribed during illness,
or to correct high preprandial blood glucose. In addition, dosage
adjustments may be required when the brand, type, or species of
insulin is changed (Teuscher 2007).
How the intervention might work
Insulin, a hormone made by beta cells of the pancreas, works on
various parts of the body when it is chemically released into the
bloodstream. This process results in the control of glucose (sugar)
levels in the blood. Normally, after you have eaten, various foods
are broken down into sugars, the main one being glucose, which
pass through the gut wall into the bloodstream. To remain healthy,
the blood glucose level should be neither too high nor too low.
For example, if the blood glucose level rises (after eating), then the
insulin level should also rise. Insulin works on the cells to make
them absorb glucose from the bloodstream, some of which is used
for energy, some of which is converted into glycogen or fat (ener-
gy stores). When blood glucose levels fall (between meals), insulin
levels fall, and the glycogen or fat is converted back into glucose,
which is released into the cells of the bloodstream. People with di-
abetes need to control the level of glucose in their blood; this is
usually tailored to their individual needs and is dependent on the
type of diabetes present. Overall, there is a lack of clear evidence
regarding the benefits and risks of the various insulin types and reg-
imens, particularly the newer insulin therapies. The evidence so far
suggests that:
• rapid-acting insulin analogues may improve postprandial hy-
perglycaemia and reduce hypoglycaemia (Siebenhofer 2006);• long-acting insulin analogues may reduce nocturnal hypogly-
caemia and weight gain (Gough 2007), but some studies found
them no better than conventional NPH insulin (Home 2005; Hor-
vath 2007);• the newer treatments seem to be safe so far (Siebenhofer 2004);• the rapid-acting insulin analogues (Aspart and Lispro) do not
seem to adversely affect pregnancy or the health of the fetus or
newborn baby (Negrato 2012);• use of isophane insulin (NPH insulin) as the first choice for
long-acting insulin during pregnancy is recommended, and in-
sulin Detemir or Glargine in women with diabetes who have es-
tablished good blood glucose control before pregnancy (NICE
2015);• twice-daily regimens using isophane insulin (NPH insulin) or
long-acting insulin analogues (insulin Glargine) may be more
suitable for those who require assistance, or have a dislike of in-
jecting (Barnett 2008);• multiple injection regimens using unmodified or soluble insulin
or rapid-acting insulin analogues, are suitable for well-motivat-
ed individuals with a good understanding of disease control, or
those with active or erratic lifestyles (NICE 2015).
The current review interventions may result in a better understand-
ing of the following outcomes in pregnant women with pre-existing
diabetes.
Improved glycaemic control: Improvement in glycaemic control
levels (i.e. optimum HbA1c levels, fasting plasma glucose).
Reduction of hypoglycaemic or hyperglycaemic episodes: A reduc-
tion or absence in the number of hyperglycaemic or hypoglycaemic
episodes reported in the trials.
Safety and efficacy: Measurement of the safety and efficacy of var-
ious insulin types and regimens.
Other: Satisfaction and quality of life reported by women; maternal
and infant outcomes.
Why it is important to do this review
Several Cochrane reviews have evaluated the effects of various in-
terventions for managing pre-existing diabetes in pregnancy, in-
cluding: early pregnancy screening to improve maternal and child
health; CSII versus MDI of insulin; glycaemic control; monitoring
blood glucose during pregnancy; and oral anti-diabetic agents
for impaired glucose tolerance (Allnutt 2015; Farrar 2016; Mid-
dleton 2012; Moy 2014; Tieu 2010a). In addition, there are other
Cochrane reviews that cover various aspects of diabetes manage-
ment around conception, pregnancy, and birth (e.g. elective deliv-
ery, exercise, antenatal breast milk expression, preconception care,
and contraceptive advice (Boulvain 2001; Ceysens 2006; East 2014;
Tieu 2010b; Visser 2013)).
Our review assessed evidence related to different insulin types
and regimens, and aimed to contribute to knowledge that will ul-
timately be used by pregnant women with pre-existing diabetes
and their clinicians, to minimise the risk of adverse birth outcomes
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and complications of diabetes for mothers. This review was time-
ly, since currently, pregnant women with diabetes have signifi-
cantly worse outcomes than women without diabetes. Achieving
improved pregnancy outcomes for women with diabetes needs
to be prioritised, particularly given that the prevalence of dia-
betes among women of childbearing age is increasing. Further-
more, while there have been advances in the different insulin types
and regimens available that have crossed into the field of obstet-
rics, further research is needed to address the safety and efficacy
of these new drugs on the market to improve compliance and gly-
caemic control, especially during pregnancy.
O B J E C T I V E S
To assess the effects of different insulin types and different insulin
regimens in pregnant women with pre-existing type 1 or type 2 di-
abetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials and cluster-randomised
trials, regardless of the number of trial arms that reported data that
evaluated different insulin types or regimens. We excluded qua-
si-randomised controlled trials and trials using a cross-over design.
We included studies published in abstract form and contacted the
authors for further details where applicable. Conference abstracts
were superseded by full publications.
Types of participants
Women with a singleton pregnancy who had pre-existing diabetes
(type 1 or type 2) and were randomised to receive different insulin
types or regimens. Trials were excluded if women were randomised
prior to pregnancy. Women who met the diagnostic criteria for GDM
were not included. Diagnostic criteria for DM and GDM were based
on various definitions as reported by individual trialists, according
to local health authorities and professional organisations. Women
were eligible regardless of gestation, age, or parity.
Types of interventions
We included randomised controlled trials that examined any of the
following comparisons.
Comparisons between dierent insulin types used within similar
insulin regimens
For example:
1. basal bolus regimen of NPH insulin given at bedtime, combined
with Aspart to cover mealtimes versus basal bolus regimen of
Glargine given at bedtime, combined with Aspart to cover meal-
times (i.e. a comparison of the effects of different insulin types
[NPH versus Glargine] when used within a basal bolus regimen).
Comparisons between dierent insulin regimens with similar
insulin types used within the regimens
For example:
1. twice-daily insulin regimen versus four times daily insulin regi-
men:
• twice-daily regimen: morning dosage = one-third human regular
insulin and two-thirds human intermediate insulin; afternoon
dosage = equal parts regular and intermediate insulin;• four-times daily regimen: first three dosages of regular insulin
30 minutes before a meal; final dosage: bedtime, intermediate
insulin.
Comparisons between dierent insulin regimens with dierent
insulin types used within the regimens
For example:
1. a biphasic insulin injected twice a day (pre-breakfast and pre-
evening meal) versus basal bolus regimen of NPH insulin given
at bedtime, combined with Aspart to cover mealtimes.
Types of outcome measures
Primary outcomes
Infant
1. Macrosomia (birthweight greater than 4000 g, birthweight
greater than 90% for gestational age at delivery after correcting
for neonatal sex and ethnicity).
2. Perinatal death.
Maternal
1. Caesarean section (emergency or elective).
2. Pre-eclampsia.
Secondary outcomes
Infant
1. Fetal anomaly divided into major and minor.
2. Birth trauma including shoulder dystocia, nerve palsy, and frac-
ture.
3. Preterm birth less than 37 weeks.
4. Small-for-gestational age at delivery (weight below the 10th per-
centile for gestational age at delivery).
5. Five-minute Apgar score less than seven.
6. Birthweight centile corrected for gestational age at delivery,
parity, ethnicity, maternal weight, and fetal sex (Z scores used
where available).
7. Admission and length of stay in neonatal intensive care unit.
8. Mechanical ventilation.
9. Neonatal infection.
10.Neonatal hypoglycaemia.
11.Insulin sensitivity (cord insulin, C-peptide).
12.Jaundice requiring therapy.
13.Respiratory distress syndrome.
14.Hyperbilirubinaemia.
15.Necrotising enterocolitis.
16.Intracranial haemorrhage.
17.Artifical tube feeding.
18.Composite outcome measure of neonatal morbidity (admission
and length of stay in neonatal intensive care unit, mechanical
ventilation, neonatal infection, neonatal hypoglycaemia, insulin
sensitivity (cord insulin, C-peptide), jaundice requiring thera-
py, respiratory distress syndrome, hyperbilirubinaemia, necro-
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tising enterocolitis, intracranial haemorrhage, artificial (tube)
feeding).
19.Neonatal anthropometry (length, head circumference, ponderal
index).
20.Neonatal adiposity (fat mass, skinfold thickness, body weight
percentile).
21.Measures of growth and neurodevelopment at childhood fol-
low-up.
Maternal
1. Vaginal delivery (spontaneous, ventouse, forceps).
2. Postpartum haemorrhage.
3. Severe perineal trauma (third- and fourth-degree tear).
4. Measures of diabetic metabolic control (levels of HbA1c, daily
mean self-monitored blood glucose, postprandial and fasting,
continuous glucose monitoring).
5. Maternal hypoglycaemia and hyperglycaemia episodes requir-
ing intervention.
6. Weight gain in pregnancy.
7. Induction of labour (reasons related to diabetes).
8. Postpartum infection.
9. Breastfeeding.
10.Retinopathy.
11.Quality of life (psychological impact of management, assessed
by psychometric testing with a reliable standardised question-
naire).
12.Use of healthcare resources (rate of antenatal clinic visits and
admission for treatment relating to control of diabetes, ultra-
sound growth scans, biophysical scans, dopplers, cardiotoco-
graph's, maternal hospital days).
13.Woman's preference and satisfaction with treatment.
14.Economic evaluation.
Outcomes not prespecified in protocol (but added to review)
Infant
1. Birthweight.
2. Infant fasting C-peptide level at three months (pmol/mL).
3. Infant C-peptide level one hour after glucose-amino acid chal-
lenge at three months (pmol/mL).
4. Infant glucose fasting level at three months (pmol/mL).
5. Infant glucose level one hour after glucose-amino acid challenge
at three months (pmol/mL).
6. Gestational age at delivery.
Maternal
1. Ventouse delivery.
2. Maternal ketonuria.
3. Maternal compliance with treatment score (1 = best compliance,
5 = worst compliance).
Search methods for identification of studies
The following methods section of this protocol is based on a stan-
dard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (30 October 2016).
The Register is a database containing over 22,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy and Childbirth’s Trials Regis-
ter, including the detailed search strategies for CENTRAL, MEDLINE,
Embase and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service, please follow this link to the editorial informa-
tion about the Cochrane Pregnancy and Childbirth in the Cochrane
Library and select the 'Specialized Register' section from the op-
tions on the leE side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials iden-
tified from:
1. monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major con-
ferences;
6. weekly current awareness alerts for a further 44 journals plus
monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is then
added to the Register. The Information Specialist searches the Reg-
ister for each review using this topic number rather than keywords.
This results in a more specific search set, which has been fully ac-
counted for in the relevant review sections (Included studies; Ex-
cluded studies).
In addition, we searched ClinicalTrials.gov and the WHO Interna-
tional Clinical Trials Registry Platform (ICTRP) for unpublished,
planned, and ongoing trial reports on 17 October 2016 (see: Appen-
dix 1 for the terms we used).
Searching other resources
We examined the reference lists of included studies and any rele-
vant studies identified. Where studies could only be accessed as ab-
stracts, we contacted the authors for more details.
We did not apply any language or date restrictions.
Data collection and analysis
The following methods section of this review are based on a stan-
dard template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors (SON, HW) independently assessed all the po-
tential studies identified as a result of the search strategy for in-
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clusion. We resolved any disagreement through discussion, or if re-
quired, we consulted a third person (ASK).
We created a study flow diagram mapping out the number of
records identified, included, and excluded.
Data extraction and management
We designed a form to extract data. For eligible studies, two re-
view authors (SON, HW) independently extracted the data using the
agreed form. We resolved discrepancies through discussion, or if re-
quired, we consulted a third person (LK). SON entered the data into
Review Manager 5 software (RevMan 5 2014) and HW checked them
for accuracy. When information regarding any of the above was un-
clear, we attempted to contact authors of the original reports to
provide further details.
Assessment of risk of bias in included studies
Two review authors (SON, HW) independently assessed risk of bias
for each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We resolved
any disagreement by discussion, or by involving a third assessor
(PK).
(1) Random sequence generation (checking for possible
selection bias)
For each included study, we described the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random number
table; computer random number generator);• high risk of bias (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number); or• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
For each included study, we described the method used to con-
ceal allocation to interventions prior to assignment, and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation; con-
secutively numbered sealed opaque envelopes);• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For each included study, we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that the
lack of blinding was unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high, or unclear risk of bias for participants;• low, high, or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For each included study, we described the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high, or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
For each included study, and for each outcome or class of out-
comes, we described the completeness of data, including attri-
tion and exclusions from the analysis. We stated whether attrition
and exclusions were reported, and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information was reported, or could
be supplied by the trial authors, we included missing data in the
analyses that we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome
data balanced across groups);• high risk of bias (e.g. numbers or reasons for missing data im-
balanced across groups; ‘as treated’ analysis done with substan-
tial departure of intervention received from that assigned at ran-
domisation);• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
For each included study, we described how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it was clear that all of the study’s pre-spec-
ified outcomes and all expected outcomes of interest to the re-
view had been reported);• high risk of bias (where not all the study’s pre-specified out-
comes had been reported; one or more reported primary out-
comes were not pre-specified; outcomes of interest were report-
ed incompletely and so could not be used; study failed to include
results of a key outcome that would have been expected to have
been reported);• unclear risk of bias.
(6) Other bias (checking for bias due to problems not covered by
(1) to (5) above)
For each included study, we described any important concerns we
had about other possible sources of bias.
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We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;• high risk of other bias;• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book of Systematic Reviews of Interventions (Higgins 2011). With ref-
erence to (1) to (6) above, we assessed the likely magnitude and di-
rection of the bias, and whether we considered it was likely to im-
pact the findings. We explored the impact of the level of bias by un-
dertaking sensitivity analyses - see Sensitivity analysis.
Assessing the quality of the body of evidence using the GRADE
approach
We created 'Summary of findings' tables for all comparisons made
in the review by importing data from Review Manager 5 (RevMan 5
2014) into the GRADEpro Guideline Development Tool. The follow-
ing outcomes were included in the 'Summary of findings' tables.
• Macrosomia.• Perinatal death.• Pre-eclampsia.• Caesarean section (emergency or elective).• Fetal anomaly.• Birth trauma, including shoulder dystocia, nerve palsy, and frac-
ture.• Composite outcome measure of neonatal morbidity (admission
and length of stay in neonatal intensive care unit, mechani-
cal ventilation, infection, jaundice requiring therapy, respiratory
distress syndrome, necrotising enterocolitis, intracranial haem-
orrhage, artificial (tube) feeding).
The quality of the evidence for each outcome was assessed us-
ing the GRADE approach as outlined in the GRADE Handbook. We
downgraded the evidence from high quality by one level for serious
(or by two levels for very serious) limitations, depending on our as-
sessments of the risk of bias, indirectness of evidence, serious in-
consistency, imprecision of effect estimates, or potential publica-
tion bias.
Measures of treatment eect
Dichotomous data
For dichotomous data, we presented results as summary risk ratios
(RR) with 95% confidence intervals (CI).
Continuous data
For continuous data, we used the mean difference (MD) if outcomes
were measured in the same way between trials. We had planned
to use the standardised mean difference (SMD) to combine trials
that measured the same outcome, but used different methods, but
there were no such trials in this review.
Unit of analysis issues
Cluster-randomised trials
We did not include any cluster-randomised trials in this review. In
future updates, if we identify eligible cluster-randomised trials, we
will include their data in the analyses along with individually-ran-
domised trials. We will adjust their sample sizes using the methods
described in the Cochrane Handbook of Systematic Reviews of Inter-
ventions (Sections 16.3.4 or 16.3.6), using an estimate of the intra
cluster correlation co-efficient (ICC) derived from the trial (if pos-
sible), from a similar trial, or from a study of a similar population.
If we use ICCs from other sources, we will report this and conduct
sensitivity analyses to investigate the effect of variation in the ICC.
If we identify both cluster-randomised trials and individually-ran-
domised trials, we will synthesise the relevant information. We will
consider it reasonable to combine the results from both if there is
little heterogeneity between the study designs, and we consider it
unlikely that there will be an interaction between the effect of the
intervention and the choice of randomisation unit.
We will also acknowledge heterogeneity in the randomisation unit
and perform a subgroup analysis to investigate the effects of the
randomisation unit.
Multi-armed trials
We included multi-armed trials and recorded all outcome data
in the review as two-arm comparisons. We included the data for
different arms in independent two-arm comparisons in separate
meta-analyses where possible. If we were unable to include the
data in separate comparisons, we combined them to create a sin-
gle pair-wise comparison (Higgins 2011). If the control group was
shared by two or more study arms, we divided the control group be-
tween relevant subgroup categories to avoid double counting the
participants. For dichotomous data, we divided the events and the
total population, while for continuous data, we assumed the same
mean and standard deviation (SD) divided by the total population.
Cross-over trials
Cross-over trials were not eligible for inclusion in this review.
Dealing with missing data
We noted levels of attrition in the included studies. If more eligible
studies are included In future updates, we will explore the impact
of including studies with high levels of missing data in the overall
assessment of the treatment effect by using sensitivity analyses.
Analyses were carried out for all outcomes, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partici-
pants were analysed in the group to which they were allocated, re-
gardless of whether they received the allocated intervention. The
denominator for each outcome in each trial was the number ran-
domised minus any participants whose outcomes were known to
be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau2, I2, and Chi2 statistics. We regarded heterogeneity as sub-
stantial if an I2 was greater than 30%, and either a Tau2 was greater
than zero, or the P was less than 0.10 in the Chi2 test for heterogene-
ity.
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Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-analy-
sis, we will investigate reporting biases (such as publication bias)
using funnel plots. We will first visually assess funnel plot asymme-
try. If asymmetry is suggested by a visual assessment, we will per-
form exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager 5 soft-
ware (RevMan 5 2014). We did not combine the results from differ-
ent trials as each trial looked at a different comparison. If we had
pooled the data in a meta-analysis, we would have used a fixed-ef-
fect model for combining data where it was reasonable to assume
that studies were estimating the same underlying treatment effect,
i.e. where trials were examining the same intervention, and the tri-
als’ populations and methods were judged to be sufficiently simi-
lar. If there was sufficient clinical heterogeneity to expect that the
underlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we had planned to use
a random-effects model to produce an overall summary, if an aver-
age treatment effect across trials was considered clinically mean-
ingful. The random-effects summary would have been treated as
the average of the range of possible treatment effects, and we had
planned to discuss the clinical implications of treatment effects dif-
fering between trials. If the average treatment effect was not clini-
cally meaningful, we had planned not to combine trials.
If we had used random-effects analyses, the results would have
been presented as the average treatment effect with 95% confi-
dence intervals, and the estimates of Tau2 and I2.
Subgroup analysis and investigation of heterogeneity
It is very unlikely that an investigation of heterogeneity will pro-
duce useful findings unless there is a substantial number of studies
(at least 10 studies for each characteristic in the meta-analysis), ac-
cording to section 9.6.5.1 in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). Had we identified substan-
tial heterogeneity, we had planned to investigate it using subgroup
analyses and sensitivity analyses, to consider whether an overall
summary was meaningful, and if it was, to use the random-effects
model to produce it.
We had planned to carry out the following subgroup analyses on
the review's primary outcomes, but there were insufficient data to
do so:
1. by type of diabetes (type 1 versus type 2);
2. gestational age when women were recruited to the trial (less
than 12 weeks versus more than 12 weeks);
3. maternal age (younger than 35 years versus older than 35 years);
4. body mass index (at or before trial entry), overweight (more than
25 kg/m2) versus normal weight (25 kg/m2 or less), and obese
(more than 30 kg/m2) versus normal weight (25 kg/m2 or less);
5. by unit of randomisation (randomised by individual participant
versus randomised by cluster).
In future updates, we plan to assess subgroup differences by inter-
action tests available in RevMan 5 (RevMan 5 2014). We will report
the results of subgroup analyses quoting the Chi2 statistic and P val-
ue, and the interaction test, I2 value.
Sensitivity analysis
We had planned to carry out the following sensitivity analyses for
the reviews primary outcomes, but there were insufficient data to
do so. In future updates, we will compare trials judged as having
a low risk of bias for allocation concealment with trials judged to
have unclear or high risk of bias, in order to assess any substantive
differences in the overall result. We will also carry out a sensitivity
analysis to explore the fixed-effect model or random-effects mod-
el analyses for primary outcomes with statistical heterogeneity. If
ICCs from other sources are used, we will conduct sensitivity analy-
ses to investigate the effect of variation in the ICC.
As noted in Section 9.7 of the Cochrane Handbook for Systematic Re-
views of Interventions, "many issues suitable for sensitivity analysis
are only identified during the review process when the individual
peculiarities of the studies under investigation are identified” (Hig-
gins 2011). If it is deemed appropriate in updates of the review to
conduct further sensitivity analyses (in addition to the pre-speci-
fied analyses outlined above), we will explain the reasons for con-
ducting these additional analyses in our review, and the analyses
will be clearly labelled as 'non-prespecified analyses'.
R E S U L T S
Description of studies
See Characteristics of included studies.
Results of the search
From the search of the Cochrane Pregnancy and Childbirth Group's
Trials Register (October 2016), we retrieved 34 full-text reports. We
also found two additional reports by searching ClinicalTrials.gov
and the WHO International Clinical Trials Registry Platform (ICTRP;
17 October 2016). When we assessed these reports for eligibility, by
applying the inclusion and exclusion criteria, we were leE with five
trials eligible to be included in the review (see Figure 1).
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
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Included studies
Design
Four trials were open-label, multi-centre, two-armed RCTs (Jo-
vanovic-Peterson 1992; Mathiesen 2007; Mathiesen 2012; Persson
2002). One trial was a single centre, four-armed RCT (Schuster
1998).
Sample sizes
There were 43 women included in the trial by Jovanovic-Peterson
1992 (N = 20 intervention arm, N = 23 control arm), 33 women in the
trial by Persson 2002 (N = 16 intervention arm, N = 17 control arm),
223 women in the trial by Mathiesen 2007 (N = 113 intervention arm,
N = 110 control arm), 162 women in the trial by Mathiesen 2012 (N
= 79 intervention arm, N = 83 control arm) and 93 women in the tri-
al by Schuster 1998 (N = 24 intervention arm1, N = 22 intervention
arm2, N = 23 intervention arm3, N = 24 control arm).
Setting
Two trials were conducted in the USA (Jovanovic-Peterson 1992;
Schuster 1998), one trial was conducted in Sweden (Persson 2002),
and the remaining two trials were conducted in 63 sites in 18 coun-
tries, and 79 sites in 17 countries respectively, mainly within Europe
(Mathiesen 2007, Mathiesen 2012).
Participants
Participants included pregnant women with type 1 DM (Jo-
vanovic-Peterson 1992; Mathiesen 2007; Mathiesen 2012; Persson
2002; Schuster 1998), or type 2 DM (Jovanovic-Peterson 1992), re-
cruited from hospitals in each specific region.
Interventions and comparisons
Dierent insulin types within similar insulin regimens
Four trials compared different insulin types within similar insulin
regimens (Jovanovic-Peterson 1992; Mathiesen 2007; Mathiesen
2012; Persson 2002).
Persson 2002 compared the rapid-acting insulin analogue Lispro
(Humalog®) plus the intermediate-acting insulin NPH (within a MDI
basal bolus regimen) to regular short-acting insulin (Humulin Reg-
ular®/Actrapid®) plus the intermediate-acting insulin NPH.
Jovanovic-Peterson 1992 compared short-acting human insulin
(recombinant deoxyribonucleic acid - Humulin®) to animal insulin.
Mathiesen 2007 compared rapid-acting insulin Aspart (plus the in-
termediate-acting insulin NPH) to human insulin (plus the interme-
diate-acting insulin NPH).
Mathiesen 2012 compared long-acting insulin Detemir (plus rapid-
acting insulin Aspart) to intermediate-acting NPH insulin (plus
rapid-acting insulin Aspart).
Dierent insulin regimens with similar insulin types used within the
regimens
One trial compared three different interventions; for the purpose of
this review, we combined the data as follows (Schuster 1998).
1. We compared pre-mixed (70 NPH/30 REG) insulin to self-mixed
split dose insulin.
2. We compared insulin injected with a Novolin pen to insulin in-
jected with a conventional needle or syringe.
Outcomes
Primary outcomes
Infant
1. Macrosomia was reported in two trials (Jovanovic-Peterson
1992; Schuster 1998).
2. Perinatal death was reported in one trial (Persson 2002).
Maternal
1. Caesarean section (emergency or elective) was reported in two
trials (Persson 2002; Schuster 1998).
2. Pre-eclampsia was reported in one trial (Persson 2002).
Secondary outcomes
Infant
1. Fetal anomaly divided into major and minor was reported in two
trials (Mathiesen 2012; Persson 2002).
2. Birth trauma, including shoulder dystocia, nerve palsy, and frac-
ture was reported in one trial (Persson 2002).
3. Preterm birth, at less than 37 weeks, was reported in one trial
(Jovanovic-Peterson 1992).
4. Small-for-gestational age at delivery (weight below the 10th per-
centile for gestational age at delivery) was reported in one trial
(Jovanovic-Peterson 1992).
5. Birthweight centile, corrected for gestational age at delivery,
parity, ethnicity, maternal weight, and fetal sex (Z scores used
where available) was reported in one trial (Jovanovic-Peterson
1992).
6. Neonatal anthropometry (length, head circumference, ponderal
index): Infant length and head circumference were reported in
one trial (Jovanovic-Peterson 1992).
7. Neonatal adiposity (fat mass, skinfold thickness, body weight
percentile): skinfold thickness and body weight percentile were
reported in one trial (Jovanovic-Peterson 1992).
Maternal
1. Vaginal delivery (spontaneous, ventouse, forceps) was reported
in one trial (Persson 2002).
2. Measures of diabetic metabolic control (levels of HbA1c, dai-
ly mean self-monitored blood glucose, post-prandial and fast-
ing, continuous glucose monitoring): levels of HbA1c at the third
trimester visit were reported in one trial (Mathiesen 2007); blood
glucose at week 14 (after lunch), was reported in one trial (Pers-
son 2002); blood glucose at weeks 21, 28, and 34 combined (after
lunch), was reported in one trial (Persson 2002); postprandial in-
crease of blood glucose before week 14 (after lunch) was report-
ed in one trial (Persson 2002); postprandial increase of blood
glucose during weeks 21, 28 and 34 combined (after lunch) was
reported in one trial (Persson 2002); antepartum capillary glu-
cose measure (mg/dL), two hours post prandial (after lunch)
was reported in one trial (Schuster 1998); insulin requirement
during pregnancy (U/kg/24 hour) was reported in one trial (Jo-
vanovic-Peterson 1992).
3. Maternal hypoglycaemia and hyperglycaemia episodes requir-
ing intervention were reported in two trials (Mathiesen 2007;
Persson 2002).
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4. Postpartum infection was reported in one trial (Schuster 1998).
5. Retinopathy was reported in one trial (Persson 2002).
6. Use of healthcare resources (rate of antenatal clinic visits and
admission for treatment relating to control of diabetes, ultra-
sound growth scans, biophysical scans, dopplers, cardiotoco-
graph's, maternal hospital days): maternal hospital days were
reported in one trial (Schuster 1998).
Outcomes not prespecified in protocol
Infant
1. Birthweight was reported in two trials (Jovanovic-Peterson
1992; Schuster 1998).
2. Infant fasting C-peptide level at three months (pmol/mL) was re-
ported in one trial (Jovanovic-Peterson 1992).
3. Infant C-peptide level 1 hour after glucose-amino acid chal-
lenge at three months (pmol/mL) was reported in one trial (Jo-
vanovic-Peterson 1992).
4. Infant glucose fasting level at three months (pmol/mL) was re-
ported in one trial (Jovanovic-Peterson 1992).
5. Infant glucose level 1 hour after glucose-amino acid challenge
at three months (pmol/mL) was reported in one trial (Jo-
vanovic-Peterson 1992).
6. Gestational age at delivery was reported in one trial (Jo-
vanovic-Peterson 1992).
Maternal
1. Ventouse delivery was reported in one trial (Persson 2002).
2. Maternal compliance with treatment score (1 = best compliance,
5 = worst compliance) was reported in one trial (Schuster 1998).
3. Maternal ketonuria was reported in one trial (Jovanovic-Peter-
son 1992).
Prespecified outcomes not reported
Infant
1. Five-minute Apgar score less than seven.
2. Admission and length of stay in neonatal intensive care unit.
3. Mechanical ventilation.
4. Neonatal infection.
5. Neonatal hypoglycaemia.
6. Insulin sensitivity (cord insulin, C-peptide).
7. Jaundice requiring therapy.
8. Respiratory distress syndrome.
9. Hyperbilirubinaemia.
10.Necrotising enterocolitis.
11.Intracranial haemorrhage.
12.Artificial (tube) feeding.
13.Composite outcome measure of neonatal morbidity (admission
and length of stay in neonatal intensive care unit, mechanical
ventilation, neonatal infection, neonatal hypoglycaemia, insulin
sensitivity (cord insulin, C-peptide), jaundice requiring thera-
py, respiratory distress syndrome, hyperbilirubinaemia, necro-
tising enterocolitis, intracranial haemorrhage, artificial (tube)
feeding).
14.Measures of growth and neurodevelopment at childhood fol-
low-up.
Maternal
1. Postpartum haemorrhage.
2. Severe perineal trauma (third- and fourth-degree tear).
3. Weight gain in pregnancy.
4. Induction of labour (reasons related to diabetes).
5. Breastfeeding.
6. Quality of life (psychological impact of management, assessed
by psychometric testing with a reliable standardised question-
naire).
7. Woman's preference and satisfaction with treatment.
8. Economic evaluation.
Excluded studies
We excluded Carr 2004 and Murphy 2011 because they used a cross-
over study design. We excluded Herrera 2015b; Kipikasa 2008;
Mohd 2012; Nachum 1999; and Nor 2007 because they included
women with gestational diabetes. Porta 2011; Reller 1985; and
Secher 2012 did not include suitable interventions. See Character-
istics of excluded studies.
Risk of bias in included studies
Overall, the five trials had a high risk of bias, due to lack of alloca-
tion concealment, lack of blinding, incomplete outcome data, and
selective reporting of outcomes (Figure 2, Figure 3).
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
Random sequence generation
Two trials described the method of sequence generation used
(computer-generated randomisation (Persson 2002; Schuster
1998)). Three trials had an unclear risk of bias, as the method of ran-
dom sequence generation was not described (Jovanovic-Peterson
1992; Mathiesen 2007; Mathiesen 2012).
Allocation concealment
Two trials provided sufficient details on the method of allocation
concealment (sealed opaque envelopes (Mathiesen 2012; Schuster
1998)). One trial had a high risk of bias for allocation concealment
(open-label (Jovanovic-Peterson 1992)). Two trials had an unclear
risk of allocation concealment, which was not reported in the trials
(Mathiesen 2007; Mathiesen 2012).
Blinding
Performance bias
It was difficult to blind the women and sta% to the interventions
of insulin types or insulin regimens. All five trials had a high risk of
performance bias, as the participants were aware of the treatment
they were receiving. For personnel, one trial reported blinding per-
sonnel to the intervention, so this was deemed to have a low risk of
bias (Schuster 1998), whilst the other four trials (Jovanovic-Peter-
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son 1992; Mathiesen 2007; Mathiesen 2012; Persson 2002) did not
blind personnel, and these were deemed to have a high risk of bias.
Detection bias
Two trials had a high risk of detection bias (open-label (Mathiesen
2007; Persson 2002)), Three trials had an unclear risk of detection
bias, which was not described in two of them (Jovanovic-Peter-
son 1992; Schuster 1998), and one trial reported blinding of out-
come assessment for only one outcome (congenital malformations
(Mathiesen 2012)).
Incomplete outcome data
Only one trial adequately described losses to follow-up, and
women were equally distributed between the four groups in this
study (Schuster 1998). Details regarding attrition bias were not re-
ported in the other four trials (Jovanovic-Peterson 1992; Mathiesen
2007; Mathiesen 2012; Persson 2002).
Selective reporting
Two trials had an unclear risk of bias, as no protocol for either trial
was available, and therefore, it was not clear whether all prespec-
ified outcomes were reported (Jovanovic-Peterson 1992; Schus-
ter 1998). Three trials were deemed to have high risk of reporting
bias (Mathiesen 2007; Mathiesen 2012; Persson 2002). In the trial by
Persson 2002, some outcomes were described as showing no differ-
ences, but these figures are not given. For two trials, we included a
subgroup of women who were pregnant at randomisation, and for
these women, very few outcomes were reported (Mathiesen 2007;
Mathiesen 2012). Contact with the authors to gain information on
this subgroup proved unsuccessful.
Other potential sources of bias
Three trials had unclear risk of bias (Mathiesen 2007; Mathiesen
2012; Persson 2002). One trial reported that there were no signifi-
cant differences between the two treatment groups with regard to
baseline characteristics, however, significantly more women in the
Lispro group had aneurysms (Persson 2002), and two trials were
funded by the pharmaceutical company Novo Nordisk© (Math-
iesen 2007; Mathiesen 2012). Two trials had a low risk of bias as it
was reported that there was no difference in baseline characteris-
tics between the two groups, which was clear from the tables (Jo-
vanovic-Peterson 1992; Schuster 1998).
Eects of interventions
See: Summary of findings for the main comparison Lispro ver-
sus regular insulin (Different insulin types within similar insulin reg-
imens); Summary of findings 2 Human insulin versus animal in-
sulin (Different insulin types within similar insulin regimens); Sum-
mary of findings 3 Pre-mixed insulin (70 NPH/30 REG) versus self-
mixed split dose insulin (Different insulin regimens with similar in-
sulin types used within the regimen); Summary of findings 4 In-
sulin injected with a Novolin pen versus insulin injected with a nee-
dle or syringe (Different insulin regimens with similar insulin types
used within the regimen); Summary of findings 5 Insulin Aspart
(+ NPH) compared to human insulin (+ NPH insulin) for pregnant
women with pre-existing diabetes (Different insulin types within
similar insulin regimens); Summary of findings 6 Insulin Detemir +
prandial insulin Aspart versus NPH insulin + prandial insulin Aspart
(Different insulin types within similar insulin regimens)
See: Summary of findings for the main comparison, Lispro versus
regular insulin (Different insulin types within similar insulin reg-
imens); Summary of findings 2, Human insulin (recombinant de-
oxyribonucleic acid - Humulin) versus animal insulin (Different in-
sulin types within similar insulin regimens); Summary of findings
3, Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose
insulin (Different insulin regimens with similar insulin types used
within the regimen); Summary of findings 4, Insulin injected with
a Novolin pen versus insulin injected with a needle/syringe (Differ-
ent insulin regimens with similar insulin types used within the regi-
men); Summary of findings 5, Insulin Aspart plus NPH insulin versus
Human insulin plus NPH insulin (Different insulin types within sim-
ilar insulin regimens); Summary of findings 6, Insulin Detemir plus
prandial insulin Aspart versus NPH insulin plus prandial insulin As-
part (Different insulin types within similar insulin regimens).
1. Lispro versus regular insulin (Dierent insulin types within
similar insulin regimens)
See Summary of findings for the main comparison. We included
one trial in this comparison, involving a total of 33 women (Pers-
son 2002). The evidence was downgraded to very low-quality for
all the outcomes supported by this trial for the following reasons:
study limitations (there was a high or unclear risk of bias for allo-
cation concealment, blinding of participants and personnel, blind-
ing of outcome assessment, incomplete outcome data, selective
outcome reporting, and other biases), and sparse data (one small
study, few events for the outcomes, very wide confidence intervals
often crossing the line of no effect).
Primary outcomes
Infant
There were no perinatal deaths in the Lispro or regular insulin
group (Analysis 1.1).
Maternal
There was very low-quality evidence from one study (33 women)
of no clear difference between insulin Lispro and regular insulin in
the primary maternal outcomes of caesarean section (risk ratio (RR)
0.59, 95% confidence interval (CI) 0.25 to 1.39; 33 women; Analy-
sis 1.2), and pregnancy-induced hypertension or pre-eclampsia (RR
0.68, 95% CI 0.35 to 1.30; Analysis 1.3).
Secondary outcomes
Infant
There was very low-quality evidence from one study (33 infants) of
no clear difference between insulin Lispro and regular insulin in the
secondary infant outcomes of fetal anomaly (RR 0.35, 95% CI 0.02
to 8.08; Analysis 1.4). There were no cases of birth trauma, including
shoulder dystocia, nerve palsy, and fracture in either group (Analy-
sis 1.5).
Maternal
There was very low-quality evidence from one study (33 women)
of no clear differences between insulin Lispro and regular insulin
in the secondary maternal outcomes of vaginal delivery (sponta-
neous, ventouse, forceps (RR 1.46, 95% CI 0.80 to 2.67; Analysis 1.6),
and measures of diabetic metabolic control: blood glucose at week
14 after lunch (mean difference (MD) -1.09 mmol/L, 95% CI -3.60 to
1.42; Analysis 1.7); blood glucose after lunch at weeks 21, 28, and 34
combined (MD -0.04 mmol/L, 95% CI -2.10 to 2.02; Analysis 1.8); in-
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crease of blood glucose after lunch before week 14 (MD 1.00 mmol/
L, 95% CI -1.52 to 3.52; Analysis 1.9); increase of blood glucose af-
ter lunch during weeks 21, 28, and 34 combined (MD 0.10 mmol/L,
95% CI -2.12 to 2.32; Analysis 1.10); maternal hypoglycaemia and
hyperglycaemia episodes requiring intervention (RR 0.21, 95% CI
0.01 to 4.10; Analysis 1.11); and retinopathy (RR 1.06, 95% CI 0.17
to 6.67; Analysis 1.12). Caution is advised in interpreting the data
where there are wide confidence intervals, small sample size, and
low event rates in this comparison.
Outcomes not prespecified in protocol
Maternal
There was very low-quality evidence from one study (33 women) of
no clear difference between insulin Lispro and regular insulin for
ventouse delivery (RR 3.19, 95% CI 0.37 to 27.58; Analysis 1.13).
Outcomes not reported
Infant
Macrosomia, preterm birth at less than 37 weeks; small-for-ges-
tational age at delivery; five-minute Apgar score less than sev-
en; birthweight centile corrected for gestational age at delivery,
parity, ethnicity, maternal weight, and fetal sex; admission and
length of stay in neonatal intensive care unit; mechanical venti-
lation; neonatal infection; jaundice requiring therapy; respiratory
distress syndrome; necrotising enterocolitis; intracranial haemor-
rhage; artificial (tube) feeding; and the composite outcome mea-
sure of neonatal morbidity (admission and length of stay in neona-
tal intensive care unit; mechanical ventilation; neonatal infection;
jaundice requiring therapy; respiratory distress syndrome; necro-
tising enterocolitis; intracranial haemorrhage; artificial (tube) feed-
ing); neonatal anthropometry (length, head circumference, pon-
deral index); neonatal adiposity (fat mass, skinfold thickness); mea-
sures of growth and neurodevelopment at childhood follow-up;
birthweight; infant fasting C-peptide level at three months; infant
C-peptide level one hour after glucose-amino acid challenge at
three months; infant glucose fasting level at three months; infant
glucose level one hour after glucose-amino acid challenge at three
months; gestational age at delivery.
Maternal
Postpartum haemorrhage; severe perineal trauma (third- and
fourth-degree tear); weight gain in pregnancy; induction of labour
(reasons related to diabetes); postpartum infection; breastfeed-
ing; quality of life (psychological impact of management, assessed
by psychometric testing with a reliable standardised question-
naire); use of healthcare resources (rate of antenatal clinic visits
and admission for treatment relating to control of diabetes, ul-
trasound growth scans, biophysical scans, dopplers, cardiotoco-
graph's); women's preference and satisfaction with treatment; an
economic evaluation; maternal ketonuria; maternal compliance
with treatment score (1 = best compliance, 5 = worst).
2. Human insulin (recombinant deoxyribonucleic acid -
Humulin) versus animal insulin (Dierent insulin types within
similar insulin regimens)
See Summary of findings 2. We included one trial in this compari-
son (Jovanovic-Peterson 1992) involving a total of 42 women. The
evidence supporting outcomes was downgraded to very low for
the following reasons: study limitations (high or unclear risk of bias
for allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selec-
tive outcome reporting, and other biases), and sparse data (one
small study, few events for the outcomes, very wide confidence in-
tervals often crossing the line of no effect).
Primary outcomes
Infant
There was very low-quality evidence from one study (42 infants) of
no clear difference between human insulin and animal insulin in
the primary infant outcome of macrosomia (RR 0.22, 95% CI 0.01 to
4.30; Analysis 2.8).
Maternal
None reported.
Secondary outcomes
Infant
There was very low-quality evidence from one study (42 infants) of
no clear differences between human insulin and animal insulin for:
preterm birth less than 37 weeks (RR 7.67, 95% CI 0.42 to 139.83,
Analysis 2.2), birthweight centile (MD -6.70%, 95% CI -23.64% to
10.24%; Analysis 2.3), infant length (MD -3.30 cm, 95% CI -6.74 to
0.14; Analysis 2.4), skinfold thickness (MD -4.10 mm, 95% CI -13.28
to 5.08; Analysis 2.5), or body weight percentile (MD -6.70%, 95%
CI -23.64 to 10.24; Analysis 2.6). The infants of women who were in
the human insulin group had a smaller mean head circumference
than those in the animal insulin group (MD -5.10 cm, 95% CI -9.52 to
-0.68; Analysis 2.7). There were no cases of babies who were small-
for-gestational age at delivery (Analysis 2.1).
Maternal
There was very low-quality evidence from one study (42 women)
that for the measure of diabetic metabolic control, women in the
human insulin group had a lower mean insulin requirement during
pregnancy (MD -0.33 U/kg/24 hour, 95% CI -0.45 to -0.21; Analysis
2.9) compared to women in the animal insulin group.
Outcomes not prespecified in protocol
Infant
There was very low-quality evidence from one study (42 infants)
that infants in the human group had a lower mean birthweight (MD
-591.00 g, 95% CI -1066.27 to -115.73; Analysis 2.10), a very slight-
ly lower infant fasting C-peptide level at three months (MD -0.07
pmol/mL, 95% CI -0.13 to -0.01; Analysis 2.11), and a lower infant C-
peptide level one hour after glucose amino acid challenge at three
months (MD -0.11 pmol/mL, 95% CI -0.19 to -0.03; Analysis 2.12). No
clear difference was found for infant glucose fasting level at three
months (MD -0.20 pmol/mL, 95% CI -0.62 to 0.22; Analysis 2.13);
infant glucose level one hour after glucose amino acid challenge
at three months (MD 0.50 pmol/mL, 95% CI -0.04 to 1.04; Analysis
2.14), or gestational age at delivery (MD 0.50 weeks, 95% CI -3.70 to
4.70; Analysis 2.15).
Maternal
There was very low-quality evidence from one study (42 women)
that the human insulin group had an unclear lower risk of maternal
ketonuria (RR 0.37, 95% CI 0.08 to 1.61; Analysis 2.16).
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Outcomes not reported
Infant
Perinatal death; fetal anomaly; birth trauma including shoulder
dystocia, nerve palsy and fracture; five-minute Apgar score less
than seven; birthweight centile corrected for gestational age at de-
livery, parity, ethnicity, maternal weight and fetal sex; admission
and length of stay in neonatal intensive care unit; mechanical ven-
tilation; neonatal infection; jaundice requiring therapy; respirato-
ry distress syndrome; necrotising enterocolitis; intracranial haem-
orrhage; artificial (tube) feeding; a composite outcome measure of
neonatal morbidity (admission and length of stay in neonatal in-
tensive care unit, mechanical ventilation, neonatal infection, jaun-
dice requiring therapy, respiratory distress syndrome, necrotising
enterocolitis, intracranial haemorrhage, artificial (tube) feeding)
and measures of growth and neurodevelopment at childhood fol-
low-up.
Maternal
Caesarean section; pre-eclampsia; vaginal delivery (spontaneous,
ventouse, forceps); postpartum haemorrhage; severe perineal
trauma (third- and fourth-degree tear); maternal hypoglycaemia
and hyperglycaemia episodes requiring intervention; weight gain
in pregnancy; induction of labour (reasons related to diabetes);
postpartum infection; breastfeeding; retinopathy; quality of life;
use of healthcare resources; women's preference and satisfaction
with treatment; an economic evaluation; ventouse delivery; and
maternal compliance with treatment score (1 = best, 5 = worst com-
pliance).
3. Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split
dose insulin (Dierent insulin regimens with similar insulin
types used within the regimen)
See Summary of findings 3. We included one trial in this comparison
(Schuster 1998) involving a total of 93 women. The evidence sup-
porting the outcomes was downgraded to very low for the follow-
ing reasons: study limitations (high or unclear risk of bias for allo-
cation concealment, blinding of participants and personnel, blind-
ing of outcome assessment, incomplete outcome data, selective
outcome reporting, and other biases), and sparse data (one small
study, few events for the outcomes, very wide confidence intervals
often crossing the line of no effect).
Primary outcomes
Infant
There was very low-quality evidence from one study (93 infants)
of no clear difference between pre-mixed insulin and self-mixed in-
sulin for macrosomia (RR 0.49, 95% CI 0.09 to 2.54; Analysis 3.1)
Maternal
There was very low-quality evidence from one study (93 women)
of no clear difference between pre-mixed insulin and self-mixed in-
sulin for caesarean section (RR 0.57, 95% CI 0.25 to 1.32; Analysis
3.2)
Secondary outcomes
Infant
None reported.
Maternal
There was very low-quality evidence from one study (93 women)
that the pre-mixed insulin group had significantly lower measures
of diabetic metabolic control, measured by antepartum capillary
glucose taken two hours after lunch (MD -11.25 mg/dL, 95% CI
-12.55 to -9.95; 10,218 tests performed on 93 women; Analysis 3.3)
compared to the self-mixed insulin group. There was no clear differ-
ence between the pre-mixed insulin and self-mixed insulin groups
for postpartum infection (endometritis; RR 0.52, 95% CI 0.26 to 1.04;
Analysis 3.4); and use of healthcare resources (maternal hospital
days; MD -0.50, 95% CI -1.40 to 0.41; Analysis 3.5)
Outcomes not prespecified in protocol
Infant
There was very low-quality evidence from one study (93 infants)
that there was no clear difference between the pre-mixed and self-
mixed insulin groups for birthweight (MD -116.56 g, 95% CI -391.81
to 158.69; Analysis 3.6).
Maternal
There was very low-quality evidence from one study (93 women)
that there was no clear difference between the two groups in terms
of the women's compliance score (ranges from 1 to 5, 1 = best, 5 =
worst; MD 0.00, 95% CI -0.87 to 0.87; Analysis 3.7).
Outcomes not reported
Infant
Perinatal death; fetal anomaly; birth trauma including shoulder
dystocia, nerve palsy and fracture; preterm birth at less than 37
weeks; small-for-gestational age at delivery; five-minute Apgar
score less than seven; birthweight centile corrected for gestation-
al age at delivery, parity, ethnicity, maternal weight and fetal sex;
admission and length of stay in neonatal intensive care unit; me-
chanical ventilation; neonatal infection; neonatal hypoglycaemia;
insulin sensitivity (cord insulin, C-peptide); jaundice requiring ther-
apy; respiratory distress syndrome; hyperbilirubinaemia; necrotis-
ing enterocolitis; intracranial haemorrhage; artificial (tube) feed-
ing; a composite outcome of neonatal morbidity (admission and
length of stay in neonatal intensive care unit, mechanical ventila-
tion, neonatal infection, neonatal hypoglycaemia, insulin sensitivi-
ty (cord insulin, C-peptide), jaundice requiring therapy, respiratory
distress syndrome, hyperbilirubinaemia, necrotising enterocolitis,
intracranial haemorrhage, artificial (tube) feeding); neonatal an-
thropometry (length, head circumference, ponderal index); neona-
tal adiposity (fat mass, skinfold thickness) and measures of growth
and neurodevelopment at childhood follow-up; infant fasting C-
peptide level at three months; infant C-peptide level one hour after
glucose-amino acid challenge at three months; infant glucose fast-
ing level at three months; infant glucose level one hour after glu-
cose-amino acid challenge at three months; gestational age at de-
livery.
Maternal
Pre-eclampsia; vaginal delivery (spontaneous, ventouse, forceps);
postpartum haemorrhage; severe perineal trauma (third- and
fourth-degree tear), maternal hypoglycaemia and hyperglycaemic
episodes requiring intervention; weight gain in pregnancy; in-
duction of labour (reasons related to diabetes); breastfeeding;
retinopathy; quality of life (psychological impact of management
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assessed by psychometric testing using a reliable standardised
questionnaire); women's preference and satisfaction with treat-
ment; an economic evaluation; ventouse delivery; maternal ke-
tonuria.
4. Insulin injected with a Novolin pen versus insulin injected
with a needle/syringe (Dierent insulin regimens with similar
insulin types used within the regimen)
See Summary of findings 4. We included one trial in this comparison
(Schuster 1998) involving a total of 93 women. The evidence for the
outcomes was downgraded to very low for the following reasons:
study limitations (high or unclear risk of bias for allocation conceal-
ment, blinding of participants and personnel, blinding of outcome
assessment, incomplete outcome data, selective outcome report-
ing, and other biases) and sparse data (one small study, few events
for the outcomes, very wide confidence intervals often crossing the
line of no effect).
Primary outcomes
Infant
There was very low-quality evidence from one study (93 infants)
of no clear difference between injecting with the Novolin pen and
a conventional needle or syringe for macrosomia (RR 0.21, 95% CI
0.03 to 1.76; Analysis 4.1).
Maternal
There was very low-quality evidence from one study (93 women) of
a difference between the two groups for caesarean section (RR 0.38,
95% CI 0.15 to 0.97; Analysis 4.2).
Secondary outcomes
Infant
None reported.
Maternal
There was very low-quality evidence from one study (93 women)
that the Novolin pen group had a lower mean measure of diabetic
metabolic control, measured by antepartum capillary glucose, tak-
en two hours after lunch (MD -7.23 mg/dL), 95% CI -8.51 to -5.95;
10,218 tests performed on 93 women; Analysis 4.3) compared to
the conventional syringe or needle group. There was no clear dif-
ference between injecting with the Novolin pen and a conventional
needle or syringe for postpartum infection (endometritis; RR 0.56,
95% CI 0.28 to 1.14; Analysis 4.4) and use of healthcare resources
(maternal hospital days; MD -0.56, 95% CI -1.45 to 0.33; Analysis
4.5).
Outcomes not prespecified in protocol
Infant
There was very low-quality evidence from one study (93 infants) of
no clear difference between injecting with the Novolin pen and a
conventional needle or syringe for birthweight (MD -162.36 g, 95%
CI -438.25 to 113.53; Analysis 4.6).
Maternal
There was very low-quality evidence from one study (93 women) of
no clear difference between the two groups in the women's compli-
ance score (ranges from 1 to 5, 1 = best compliance, 5 = worst com-
pliance; MD -0.21, 95% CI -0.83 to 0.41; Analysis 4.7).
Outcomes not reported
Infant
Perinatal death; fetal anomaly; birth trauma including shoulder
dystocia, nerve palsy and fracture; preterm birth at less than 37
weeks; small-for-gestational age at delivery; five-minute Apgar
score less than seven; birthweight centile corrected for gestation-
al age at delivery, parity, ethnicity, maternal weight and fetal sex;
admission and length of stay in neonatal intensive care unit; me-
chanical ventilation; neonatal infection; neonatal hypoglycaemia;
insulin sensitivity (cord insulin, C-peptide); jaundice requiring ther-
apy; respiratory distress syndrome; hyperbilirubinaemia; necrotis-
ing enterocolitis; intracranial haemorrhage; artificial (tube) feed-
ing; a composite outcome of neonatal morbidity (admission and
length of stay in neonatal intensive care unit, mechanical ventila-
tion, neonatal infection, neonatal hypoglycaemia, insulin sensitivi-
ty (cord insulin, C-peptide), jaundice requiring therapy, respiratory
distress syndrome, hyperbilirubinaemia, necrotising enterocolitis,
intracranial haemorrhage, artificial (tube) feeding); neonatal an-
thropometry (length, head circumference, ponderal index); neona-
tal adiposity (fat mass, skinfold thickness) and measures of growth
and neurodevelopment at childhood follow-up; infant fasting C-
peptide level at three months; infant C-peptide level one hour after
glucose-amino acid challenge at three months; infant glucose fast-
ing level at three months; infant glucose level one hour after glu-
cose-amino acid challenge at three months; gestational age at de-
livery.
Maternal
Pre-eclampsia; vaginal delivery (spontaneous, ventouse, forceps);
postpartum haemorrhage; severe perineal trauma (third- and
fourth-degree tear), maternal hypoglycaemia and hyperglycaemic
episodes requiring intervention; weight gain in pregnancy; in-
duction of labour (reasons related to diabetes); breastfeeding;
retinopathy; quality of life (psychological impact of management,
assessed by psychometric testing using a reliable standardised
questionnaire); women's preference and satisfaction with treat-
ment; an economic evaluation; ventouse delivery; maternal ke-
tonuria.
5. Insulin Aspart + NPH insulin versus Human insulin + NPH
insulin (Dierent insulin types within similar insulin regimens)
See Summary of findings 5. We included one trial in this comparison
(Mathiesen 2007) involving a total of 223 women. This is an empty
'summary of findings' table with no evidence or quality assessment
as none of the primary outcomes were included in this trial.
Primary outcomes
Infant
None reported.
Maternal
None reported.
Secondary outcomes
Infant
None reported.
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Maternal
There was very low-quality evidence from one study (223 women)
of no difference between insulin Aspart and human insulin for dia-
betic metabolic control, measured by A1c at third trimester visits
(MD -0.10%, 95% CI -0.28 to 0.08; Analysis 5.1, average plasma glu-
cose at third trimester visits (MD -0.20 mmol/L, 95% CI -0.53 to 0.13;
Analysis 5.2); and maternal hypoglycaemic episodes (RR 1.06, 95%
CI 0.99 to 1.14; Analysis 5.3);
Outcomes not prespecified in protocol
Infant
None.
Maternal
None.
Outcomes not reported
Infant
Macrosomia; perinatal death; fetal anomaly; birth trauma including
shoulder dystocia, nerve palsy and fracture; preterm birth less than
37 weeks; small-for-gestational age at delivery; five-minute Apgar
score less than seven; birthweight centile corrected for gestation-
al age at delivery, parity, ethnicity, maternal weight and fetal sex;
admission and length of stay in neonatal intensive care unit; me-
chanical ventilation; neonatal infection; neonatal hypoglycaemia;
insulin sensitivity (cord insulin, C-peptide); jaundice requiring ther-
apy; respiratory distress syndrome; hyperbilirubinaemia; necrotis-
ing enterocolitis; intracranial haemorrhage; artificial (tube) feed-
ing; a composite outcome measure of neonatal morbidity (admis-
sion and length of stay in neonatal intensive care unit, mechanical
ventilation, neonatal infection, neonatal hypoglycaemia, insulin
sensitivity (cord insulin, C-peptide), jaundice requiring therapy,
respiratory distress syndrome, hyperbilirubinaemia, necrotising
enterocolitis, intracranial haemorrhage, artificial (tube) feeding);
neonatal anthropometry (length, head circumference, ponderal in-
dex); neonatal adiposity (fat mass, skinfold thickness) and mea-
sures of growth and neurodevelopment at childhood follow-up;
birthweight; infant fasting C-peptide level at three months; infant
C-peptide level one hour after glucose-amino acid challenge at
three months; infant glucose fasting level at three months; infant
glucose level one hour after glucose-amino acid challenge at three
months; gestational age at delivery.
Maternal
Caesarean section; pre-eclampsia; vaginal delivery (spontaneous,
ventouse, forceps); postpartum haemorrhage; severe perineal
trauma (third- and fourth-degree tear); weight gain in pregnancy;
induction of labour (reasons related to diabetes); postpartum in-
fection; breastfeeding; retinopathy; quality of life (psychological
impact of management, assessed by psychometric testing using a
reliable standardised questionnaire); use of healthcare resources
(rate of antenatal clinic visits and admission for treatment relat-
ing to diabetic control, ultrasound growth scans, biophysical scans,
dopplers, cardiotocograph's); women's preference and satisfac-
tion with treatment; an economic evaluation; ventouse delivery;
maternal ketonuria; maternal compliance with treatment score (1
= best, 5 = worst compliance).
6. Insulin Detemir + Aspart versus NPH insulin + Aspart
(Dierent insulin types within similar insulin regimens)
See Summary of findings 6. We included one trial in this compari-
son (Mathiesen 2012) involving a total of 162 women. The evidence
for the outcomes supported by this study was downgraded to very
low for study limitations (high or unclear risk of bias for allocation
concealment, blinding of participants and personnel, incomplete
outcome data, selective outcome reporting, and other biases) and
sparse data (one small study, few events for the outcomes, very
wide confidence intervals often crossing the line of no effect).
Primary outcomes
Infant
None reported.
Maternal
None reported.
Secondary outcomes
Infant
There was very low-quality evidence from one study (162 infants)
of no clear difference in the number of major fetal anomalies in
the insulin Detemir group compared to the NPH insulin group (RR
3.15, 95% CI 0.33 to 29.67; Analysis 6.1), major fetal anomalies (RR
2.10, 95% CI 0.19 to 22.72; Analysis 6.2); minor fetal anomalies (RR
0.35, 95% CI 0.01 to 8.47; Analysis 6.3), and minor fetal anomalies
(RR 1.05, 95% CI 0.22 to 5.05; Analysis 6.4). Outcome assessors were
blinded for Analyses 6.1 and 6.3 and unblinded for Analyses 6.2 and
6.4.
Maternal
Outcomes not prespecified in protocol
Infant
None.
Maternal
None.
Outcomes not reported
Infant
Macrosomia; perinatal death; birth trauma including shoulder dys-
tocia, nerve palsy and fracture; preterm birth less than 37 weeks;
small-for-gestational age at delivery; five-minute Apgar score less
than seven; birthweight centile corrected for gestational age at de-
livery, parity, ethnicity, maternal weight and fetal sex; admission
and length of stay in neonatal intensive care unit; mechanical ven-
tilation; neonatal infection; neonatal hypoglycaemia; insulin sen-
sitivity (cord insulin, C-peptide); jaundice requiring therapy; respi-
ratory distress syndrome; hyperbilirubinaemia; necrotising entero-
colitis; intracranial haemorrhage; artificial (tube) feeding; a com-
posite outcome measure of neonatal morbidity (admission and
length of stay in neonatal intensive care unit, mechanical ventila-
tion, neonatal infection, neonatal hypoglycaemia, insulin sensitivi-
ty (cord insulin, C-peptide), jaundice requiring therapy, respiratory
distress syndrome, hyperbilirubinaemia, necrotising enterocolitis,
intracranial haemorrhage, artificial (tube) feeding); neonatal an-
thropometry (length, head circumference, ponderal index); neona-
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tal adiposity (fat mass, skinfold thickness) and measures of growth
and neurodevelopment at childhood follow-up; birthweight; infant
fasting C-peptide level at three months; infant C-peptide level one
hour after glucose-amino acid challenge at three months; infant
glucose fasting level at three months; infant glucose level one hour
after glucose-amino acid challenge at three months; gestational
age at delivery.
Maternal
Caesarean section; pre-eclampsia; vaginal delivery (spontaneous,
ventouse, forceps); postpartum haemorrhage; severe perineal
trauma (third- and fourth-degree tear); measures of diabetic meta-
bolic control (levels of HbA1c, daily mean self-monitored blood
glucose, post-prandial and fasting, continuous glucose monitor-
ing); maternal hypoglycaemia and hyperglycaemic episodes re-
quiring intervention; weight gain in pregnancy; induction of labour
(reasons related to diabetes); postpartum infection; breastfeeding;
retinopathy; quality of life (psychological impact of management,
assessed by psychometric testing using a reliable standardised
questionnaire); use of healthcare resources (rate of antenatal clin-
ic visits and admission for treatment relating to diabetic control,
ultrasound growth scans, biophysical scans, dopplers, cardiotoco-
graph's); women's preference and satisfaction with treatment; an
economic evaluation; ventouse delivery; maternal ketonuria; ma-
ternal compliance with treatment score (1 = best, 5 = worst compli-
ance).
D I S C U S S I O N
There are many different types of insulin (e.g. human, animal), and
many different insulin regimens (e.g. injection of insulin via a pen
or injection of insulin with a conventional needle or syringe). This
review sought to investigate whether any particular type of insulin
or any particular regimen was safer or more effective for improving
maternal and fetal health and well-being in pregnant women with
pre-existing type 1 or type 2 diabetes.
Summary of main results
This review included five trials, with a total of 554 women and 554
babies. We could not determine whether there were any clear dif-
ferences for the primary infant outcomes (macrosomia and perina-
tal death) or primary maternal outcomes (caesarean section and
pregnancy-induced hypertension or pre-eclampsia) for each of the
comparisons of different insulin types (Lispro versus regular insulin
Summary of findings for the main comparison; Human insulin ver-
sus animal insulin Summary of findings 2; Insulin Aspart versus hu-
man insulin Summary of findings 5; and Insulin Detemir versus NPH
insulin Summary of findings 6), or for the different insulin regimens
(Pre-mixed insulin versus self-mixed insulin Summary of findings
3; and Insulin injected with a Novolin pen versus insulin injected
with a conventional needle or syringe Summary of findings 4), since
many were not reported in the trials, and secondly, where they were
reported, the data were from a single, small trial. There were also
no clear differences found for the secondary infant and maternal
outcomes. In one trial, human insulin was associated with a low-
er mean insulin requirement during pregnancy, compared with the
animal insulin group. In another trial, pre-mixed insulin was associ-
ated with a lower antepartum capillary glucose measurement two
hours postprandial (after lunch) when compared with self-mixed
insulin. The same was found when the Novolin pen was compared
with the conventional needle or syringe. In addition, there were
fewer caesarean sections in the Novolin pen group compared with
the conventional needle or syringe group. Many important out-
comes were not reported in these trials including most primary out-
comes and secondary infant and maternal outcomes. There was no
long-term follow-up of infants in these studies, and information on
healthcare use and satisfaction with insulin treatments was lack-
ing.
Overall completeness and applicability of evidence
Overall, we only included five trials in this review that included
pregnant women with pre-existing diabetes. It was difficult to draw
any firm conclusions from the trials, or to say that they were gener-
alisable to the general pregnant population for many reasons. First
of all, the sample sizes in the trials were small. Second, many of the
review's primary prespecified outcomes were not reported, for ex-
ample, perinatal death and pre-eclampsia were each reported in
only one trial, and macrosomia and caesarean section were each
reported in only two trials. Further trials in pregnant women are re-
quired that are adequately powered, and that report all outcomes
suggested in this review, to evaluate the different insulin types and
regimens.
Quality of the evidence
The trials included in this review were small. Overall, the quality of
reporting was poor, and therefore, risk of bias in all trials was either
high or unclear. All of the trials were open trials, as it is difficult to
blind participants or clinicians to the intervention allocation in tri-
als such as those included in this review. However, outcome asses-
sors could have been blinded but were not in the majority of the tri-
als. We do not know if the pregnant women included in these trials
were representative of the general population of women with pre-
existing type 1 or type 2 diabetes, but researchers should try to en-
sure that their trial populations reflect the general obstetric popu-
lation as much as possible.
Most primary outcomes were not reported. For those that were re-
ported, our GRADE assessment was that the quality of the evidence
was very low (caesarean section, pregnancy-induced hypertension
or pre-eclampsia, fetal anomaly, birth trauma, and macrosomia).
This was because there was only a single study for each compari-
son, so pooling of the data was not possible, there were design lim-
itations in the included trials (high or unclear risk of bias for alloca-
tion concealment, blinding of participants and personnel, blinding
of outcome assessment, incomplete outcome data, selective out-
come reporting and other biases) and sparse data (small sample
sizes, wide confidence intervals that crossed the line of no effect,
and few or no events). These judgements are shown in the Sum-
mary of findings for the main comparison, Summary of findings 2,
Summary of findings 3, Summary of findings 4, and Summary of
findings 6. We were unable to populate Summary of findings 5, be-
cause our primary outcomes were not reported for this compari-
son. Therefore, we could not conclude whether one type of insulin
or one insulin regimen was better in pregnant women with pre-ex-
isting diabetes for improving maternal and infant outcomes.
Potential biases in the review process
Risk of bias assessment is a subjective process. This can be min-
imised by following the procedures outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011), where-
by two or more review authors independently assess studies and
resolve any disagreement through discussion, involving a third as-
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sessor to reach consensus as required. In this review, we undertook
a comprehensive and systematic search of databases to reduce the
potential for publication bias, and did not apply any language, date,
or publication status restrictions.
Agreements and disagreements with other studies or
reviews
Our findings, that the limited number of trials that provided very
low-quality evidence, restricted us from drawing any meaningful
or scientific conclusions regarding the safety and effectiveness of
one type of insulin over the other, or one insulin regimen over the
other, in pregnant women with pre-existing type 1 or type 2 dia-
betes. This was also the case in other reviews (Farrar 2016; Horvath
2007; Siebenhofer 2006). All reported that there was no evidence of
any clear benefit of one insulin type or regimen over the other, and
that large, randomised trials of better methodological quality are
required. One review found that long-acting insulin preparations
seemed to have a beneficial effect on nocturnal glucose levels; their
overall diabetes control was described as clinically unremarkable
(Vardi 2008). This review included three very large randomised con-
trolled trials but concluded that the findings warranted further sub-
stantiation. This review was not in pregnant women.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
At present, insufficient data exist to allow the review authors to
make any substantial or concrete conclusions about the effec-
tiveness of one insulin type or regimen over another in pregnant
women with pre-existing type 1 or type 2 diabetes. Therefore, deci-
sions about the use of different types of insulin and different insulin
regimens for pregnant women with pre-existing type 1 or type 2 di-
abetes should be made according to individual needs and available
resources.
Implications for research
Large, multi-centred trials, which are adequately randomised, suf-
ficiently powered, and clearly reported are needed to assess the
safety and effectiveness of different insulin types and regimens
in pregnant women with pre-existing type 1 or type 2 diabetes. It
would be very helpful if outcomes across trials were consistently
defined and reported. In addition, it is difficult to blind women and
caregivers to their randomised allocation because of the nature
of the intervention of interest. However, it is possible to blind the
outcome assessor to treatment allocation, which is strongly rec-
ommended. Any blinding should be clearly stated in the trial re-
port. Future trials should undertake a longer period of follow-up of
women and their infants, as well as the cost-effectiveness of vari-
ous insulin types and regimens.
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Characteristics of included studies [ordered by study ID]
 
Methods RCT (open-label, 2-centre, 2-arm).
Participants 43 insulin-requiring pregnant women with diabetes (type 1 or 2).
Recruited between 1983 and 1985.
Setting: The Children's Hospital of San Francisco and Cornell University Medical College, New York.
Inclusion criteria: pregnant women with type 1 or 2 diabetes; < 20 weeks' gestation; aged > 18 years old;
treated with animal insulin for at least 24 months; bodyweight within 20% of ideal body weight as de-
termined by the Metropolitan Life tables.
Exclusion criteria: women with hypertension (blood pressure > 140/90 mmHg); serum creatine higher
than the upper range of normal; advanced cardiovascular disease; history of Addison's disease or pitu-
itary insufficiency; local or systemic allergy to animal source insulin; pre-pregnancy insulin dose greater
than 1.5 U/kg per 24 hours, history of treatment human insulin or an insulin infusion device.
Interventions Human insulin (recombinant deoxyribonucleic acid - Humulin); N = 20.
Outcomes Infant
Jovanovic-Peterson 1992 
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Gestational age at delivery
Percentile body weight
Skinfold thickness
Length
Weight
Head circumference
Large-for-gestational age at delivery
Small-for-gestational age at delivery
C-peptide level (pmol/mL)
Glucose level (mmol)
Preterm delivery
Appropriate-for-gestational age at delivery
Macrosomia (birthweight > 4000 g)
Maternal
Temperature
Systolic blood pressure
Diastolic blood pressure
Resting heart rate
Edema
Renal function
Complete blood cell count
Chemistry profile
Calories consumed
Weight gain
Glycohemoglobin levels
Maternal ketonuria
Mean insulin dose requirement
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Women were randomly assigned to treatment with either human or their cur-
rent animal insulin. However, there was no description of the method used.
Allocation concealment
(selection bias)
High risk Open-label trial.
Jovanovic-Peterson 1992  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Participants: no. Open-label trial.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Personnel: no. Open-label trial.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not described.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 1 woman (out of 23) randomised to the animal insulin group did not complete
the admission visit or return for follow-up. She was excluded from the statis-
tical analysis. Not all babies were included in the reporting of large-for-gesta-
tional age at delivery.
Selective reporting (re-
porting bias)
Unclear risk This study was assessed from the published report. No protocol was available,
so we do not know if all pre-specified outcomes were reported.
Other bias Low risk It was reported that the baseline characteristics of groups showed a remark-
ably similar population of women in both groups.
Jovanovic-Peterson 1992  (Continued)
 
 
Methods 2 arm RCT (open-label, parallel group, multi-centre).
Participants Setting: 63 sites in 18 countries, mainly within Europe.
Inclusion criteria: women ≥ 18 years with insulin-treated type 1 diabetes for ≥ 12 months. Women were
either pregnant with a singleton pregnancy (gestational age at delivery ≤ 10 weeks; N = 223, included in
this review), or planning to become pregnant (N = 99, excluded from this review). A1c was ≤ 8% at con-
firmation of pregnancy.
Exclusion criteria: women with multiple pregnancy, fertility treatment, clinically significant gynaeco-
logical conditions, diabetic nephropathy or medical problems, a previous child born with major con-
genital malformations, multiple miscarriage, or stillbirths (more than 2). Women not pregnant within
12 months of randomisation.
Interventions Experimental: prandial insulin Aspart (100 units/mL: Novo Nordisk, Basvaerd, Denmark) + NPH insulin.
1 to 4 subcutaneous injections per day (lowest available at centre) using the Novo pen. N = 113 (ran-
domised when pregnant).
Comparison: prandial human insulin (100 IU/mL; Novo Nordisk) + NPH insulin. 1 to 4 subcutaneous in-
jections per day (lowest available at centre) using the Novo pen. N = 110 (randomised when pregnant).
Outcomes Many outcomes were reported for all women in the study: major hypoglycaemia requiring third-party
assistance, minor hypoglycaemia, maternal death, hypoglycaemic coma, inadequate glycaemic con-
trol, hyperglycaemia, pre-eclampsia, preterm labour, emergency caesarean section, glycaemic control,
A1c, plasma glucose profile breakfast, lunch, dinner, mean insulin dose), abortion, caesarean section,
induced abortion, stillbirth, QoL assessments.
However, few of these were reported separately for women randomised during pregnancy.
Mathiesen 2007 
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Notes SON contacted the authors to request additional data. A web site link was received, but did not allow
access to the data. We received no responses to further requests.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk States that women were 'randomised', but no further description of method
was given.
Allocation concealment
(selection bias)
Unclear risk No description.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Participants: no. Open-label trial.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Personnel: no. Open-label trial.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk All women in the subgroup included in the review were accounted for. Women
who were not pregnant ≤ 12 months after randomisation were withdrawn
from the study: potential bias in conception rates between groups affected the
overall study, but not the subgroup included in the review.
Selective reporting (re-
porting bias)
High risk Very few outcomes were reported for the subgroup of women who were ran-
domised during pregnancy.
Other bias Unclear risk The report declared that the trial was sponsored by Novo Nordisk. It was un-
clear whether this conflict of interest introduced any bias.
Mathiesen 2007  (Continued)
 
 
Methods 2-arm RCT, open label, parallel group, multi-centre.
Participants Setting: 79 different sites in 17 countries.
Inclusion criteria: Women ≥ 18 years with insulin-treated type 1 diabetes for ≥ 12 months before ran-
domisation. They were either pregnant with a singleton pregnancy (gestational age at delivery 8 to 12
weeks; N = 162, included in this review), or planning to become pregnant (N = 148, excluded from this
review). A1c was ≤ 8% at confirmation of pregnancy.
Exclusion criteria: women with impaired hepatic or renal function or uncontrolled hypertension (sys-
tolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or both), undergoing medical
infertility treatment, or who had been previously randomised in this trial. Women not pregnant within
12 months of randomisation.
Interventions Experimental intervention: Insulin Detemir (100 units/mL) with prandial insulin Aspart (100 units/mL) in
a basal bolus regimen (1:1), subcutaneous injections administered from randomisation until termina-
tion or 6 weeks postdelivery. N = 79 (randomised when pregnant).
Mathiesen 2012 
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Control/Comparison intervention: NPH insulin (100 IU/mL) with prandial insulin Aspart (100 units/mL)
in a basal bolus regimen (1:1), subcutaneous injections administered from randomisation until termi-
nation or 6 weeks postdelivery. N = 83 (randomised when pregnant).
Basal insulin dose was titrated according to fasting or pre-dinner capillary plasma glucose values. All
bolus insulin doses were titrated according to pre- and postprandial plasma glucose values. Preprandi-
al PG target of 72 to 108 mg/dL (4.0-6.0 mmol/L) and 2-hour postprandial glucose target < 126 mg/dL (<
7.0 mmol/L).
Outcomes Many outcomes were reported for all women in the study: hypoglycaemia, glycaemic control including
A1c, insulin dose, adverse events, pregnancy outcomes.
However, few of these were reported separately for women randomised during pregnancy.
Notes SON contacted the authors to request additional data. A web site link was received, but did not allow
access to the data. We received no responses to further requests.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described.
Allocation concealment
(selection bias)
Low risk “Subjects were randomised 1:1 (using Interactive Voice/Web Response Sys-
tem)."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Participants: no. Open-label trial.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk .Personnel: no. Open-label trial.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Open-label. Congenital malformations were assessed by 2 independent ex-
perts, 1 of whom was blinded to group allocation.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk All women in the subgroup included in the review were accounted for. Women
who were not pregnant ≤ 12 months after randomisation were withdrawn
from the study: potential bias in conception rates between groups affected the
overall study, but not the subgroup included in the review.
Selective reporting (re-
porting bias)
High risk Very few outcomes were reported for the subgroup of women who were ran-
domised during pregnancy.
Other bias Unclear risk The report declared that the trial was sponsored by Novo Nordisk. It was un-
clear whether this conflict of interest introduced any bias.
Mathiesen 2012  (Continued)
 
 
Methods RCT (open-label, multi-centre, 2-arm).
Persson 2002 
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Participants 33 pregnant women with type 1 diabetes recruited at 6 to 8 weeks' gestation and entered into the study
at 15 weeks' gestation.
Setting: 4 centres in Sweden. The Departments of Obstetrics and Gynaecology in Huddinge Hospital,
Karolinska Hospital, Södersjukhuset in Stockholm, and Örebro Regional Hospital.
Inclusion criteria: pregnant women with type 1 diabetes; duration of diabetes for a minimum of 2 years;
aged 20 years or more; multiple dose regimen with regular and NPH insulin; Initial HbA1c value below
9%.
Exclusion criteria: gestational or type 2 diabetes; duration of diabetes less than 2 years; aged younger
than 20 years; In receipt of insulin lispro (intervention); HbA1c value greater than 9%.
Interventions Preprandial rapid-acting insulin lispro (Humalog®) in combination with NPH in a MDI regimen with ad-
ministration of lispro or regular insulin immediately before or 30 minutes before meals, respective-
ly. Medium-acting NPH insulin was administered at bedtime and when needed before breakfast. All
women were given dietary instruction by a dietician. Blood glucose targets were pre- and postprandial
levels of < 5.0 and < 6.5 mmol/l respectively. N = 16.
Outcomes Infant
Gestational age at delivery
Birthweight
Length
Appropriate-for-gestational age at delivery
Small-for-gestational age at delivery
Large-for-gestational age at delivery
Malformation
Birth trauma
Asphyxia
Respiratory distress
Hypoglycaemia
Hyperbilirubinemia
Perinatal death
Maternal
Micoangiopathy
Glycaemic control (HbA1c, blood glucose, hypoglycaemia)
Retinopathy
Mode of delivery
Hypertension
Pre-eclampsia
Polyhydamniosis
Notes  
Persson 2002  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was conducted at a central site according to 4-patient block
model (AABB, etc.).
Allocation concealment
(selection bias)
Unclear risk Not described.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Participants: no. Open-label trial.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Personnel: no. Open-label trial.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label trial.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The report indicated that 7 women did not satisfy the inclusion criteria and 2
were unwilling to participate. These appeared to be in addition to those ran-
domised, but it was unclear if these women were randomised and then with-
drawn from the study.
Selective reporting (re-
porting bias)
High risk The trial was assessed from the published report, with no protocol available.
It was not clear whether all prespecified outcomes were reported. Some out-
comes were described as showing no differences, but these figures were not
given: gestational age at delivery, birthweight, rate of large-for-gestational-age
infants, neonatal complications.
Other bias Unclear risk It was reported that there were no significant differences between the 2 treat-
ment groups with regard to baseline characteristics, however, significantly
more women in the lispro group had aneurysms.
Persson 2002  (Continued)
 
 
Methods RCT (single-blinded, 1 centre, 4-arm).
Participants 93 pregnant women with type 1 or 2 diabetes.
Setting: University of Mississippi Medical Centre, USA.
Inclusion criteria: insulin-dependent diabetes; maternal age 15 to 44 years; < 20 weeks' gestation at en-
try; willingness to sign an informed consent form.
Exclusion criteria: additional pregnancy complications which might affect maternal or infant outcome
(hypertension, placenta praevia, fetal malformations, and glucose intolerance not requiring insulin);
unwillingness to comply with prenatal care or aggressive glucose control; women's refusal to partici-
pate.
Interventions Women were enrolled into 4 groups.
Schuster 1998 
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Intervention 1: pre-mixed insulin (70 NPH/30 REG) administered with a needle or syringe (N = 24).
Intervention 2: self-mixed split dose regular and NPH insulin administered with a Novolin® pen (N = 22).
Intervention 3: pre-mixed insulin (70 NPH/30 REG) administered with a Novolin® pen (N = 23).
Control: self-mixed split dose regular and NPH insulin administered with a needle or syringe (N = 24).
Outcomes Infant
Gestational age at delivery
Preterm delivery
Infant birthweight
Macrosomia
1- and 5-minute Apgar score
Hyperbilirubinemia
Hypoglycaemia
Hypocalcemia
Incidence of admission to the neonatal unit
Maternal
Caesarean delivery for cephalo-pelvic disproportion
Pregnancy-induced hypertension
Capillary glucose measurements (mg/DL)
Abruption
Chorioamnionitis
Endometritis
Maternal hospital days
Number of prenatal visits
Overall patient compliance (based on dietary assessment, adequate glucose monitoring, insulin usage,
appropriate follow-up with physician instructions, and visits) scored from 1 to 5, with 1 implying good
compliance and 5 implying poor compliance
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was carried out by selecting an opaque, consecutively-num-
bered envelope in which computer-generated randomisation cards were
placed, to assign women into 1 of 4 groups.
Allocation concealment
(selection bias)
Low risk Randomisation was carried out by selecting an opaque, consecutively-num-
bered envelope in which computer-generated randomisation cards were
placed, to assign women into 1 of 4 groups.
Schuster 1998  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Participants: no. Open-label trial.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Personnel: yes. Sta% managing the women were unaware of the treatment reg-
imen to which the women were assigned, during the antepartum period.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not described.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Of the 100 women enrolled, 93 were available for outcome analysis. 2 women
suffered spontaneous abortions, 2 underwent elective terminations and 3
were lost to follow-up. These 7 women were equally distributed between the 4
groups.
Selective reporting (re-
porting bias)
Unclear risk This trial was assessed from the published report, with no protocol available.
It was not clear whether all prespecified outcomes were reported. Some out-
comes were described as showing no differences, but the figures were not giv-
en: caesarean section for any indication, incidence of pregnancy-induced hy-
pertension, preterm labour, infant hyperbilirubinaemia, and hypoglycaemia. It
was unclear whether caesarean section for cephalo-pelvic disproportion was a
pre-specified outcome, or included because it showed a significant difference
between groups.
Other bias Low risk There were no significant differences between the treatment groups with re-
gard to baseline characteristics.
Schuster 1998  (Continued)
RCT: randomised controlled trial
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Carr 2004 Cross-over trial design.
Herrera 2015b Included women with gestational diabetes.
Kipikasa 2008 Included women with gestational diabetes.
Mohd 2012 Included women with gestational diabetes.
Murphy 2011 Cross-over trial design.
Nachum 1999 Included women with gestational diabetes.
Nor 2007 Included women with gestational diabetes.
Porta 2011 Did not include the intervention: randomisation prior to pregnancy.
Reller 1985 Did not include the intervention: not a randomised controlled trial.
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Study Reason for exclusion
Secher 2012 Did not include the intervention: a trial of glucose monitoring not insulin regimen.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Lispro versus regular insulin (Dierent insulin types within similar insulin regimens)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Perinatal death 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Caesarean section 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.25, 1.39]
3 Pregnancy-induced hypertension
and pre-eclampsia
1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.35, 1.30]
4 Fetal anomaly 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.02, 8.08]
5 Birth trauma, including shoulder dys-
tocia, nerve palsy, and fracture
1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Vaginal delivery (spontaneous, ven-
touse, forceps)
1 33 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.80, 2.67]
7 Blood glucose (mmol/L) week 14 (af-
ter lunch)
1 33 Mean Difference (IV, Fixed, 95% CI) -1.09 [-3.60, 1.42]
8 Blood glucose (mmol/L) weeks 21,
28, and 34 combined (after lunch)
1 33 Mean Difference (IV, Fixed, 95% CI) -0.04 [-2.10, 2.02]
9 Postprandial increase of blood glu-
cose (mmol/L) before week 14 (lunch)
1 33 Mean Difference (IV, Fixed, 95% CI) 1.0 [-1.52, 3.52]
10 Postprandial increase of blood glu-
cose (mmol/L) during weeks 21, 28,
and 34 combined (lunch)
1 33 Mean Difference (IV, Fixed, 95% CI) 0.10 [-2.12, 2.32]
11 Maternal hypoglycaemia and hyper-
glycaemia episodes requiring interven-
tion
1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.10]
12 Retinopathy 1 33 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.17, 6.67]
13 Ventouse delivery 1 33 Risk Ratio (M-H, Fixed, 95% CI) 3.19 [0.37, 27.58]
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Analysis 1.1.   Comparison 1 Lispro versus regular insulin (Dierent
insulin types within similar insulin regimens), Outcome 1 Perinatal death.
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Persson 2002 0/16 0/17   Not estimable
   
Total (95% CI) 16 17 Not estimable
Total events: 0 (Lispro insulin), 0 (Regular insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Lispro 100.1 50.2 20.5 1 Favours Regular insulin
 
 
Analysis 1.2.   Comparison 1 Lispro versus regular insulin (Dierent insulin
types within similar insulin regimens), Outcome 2 Caesarean section.
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Persson 2002 5/16 9/17 100% 0.59[0.25,1.39]
   
Total (95% CI) 16 17 100% 0.59[0.25,1.39]
Total events: 5 (Lispro insulin), 9 (Regular insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.21(P=0.23)  
Favours Lispro 50.2 20.5 1 Favours Regular insulin
 
 
Analysis 1.3.   Comparison 1 Lispro versus regular insulin (Dierent insulin types within
similar insulin regimens), Outcome 3 Pregnancy-induced hypertension and pre-eclampsia.
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Persson 2002 7/16 11/17 100% 0.68[0.35,1.3]
   
Total (95% CI) 16 17 100% 0.68[0.35,1.3]
Total events: 7 (Lispro insulin), 11 (Regular insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.17(P=0.24)  
Favours Lispro 50.2 20.5 1 Favours Regular insulin
 
 
Analysis 1.4.   Comparison 1 Lispro versus regular insulin (Dierent
insulin types within similar insulin regimens), Outcome 4 Fetal anomaly.
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Persson 2002 0/16 1/17 100% 0.35[0.02,8.08]
   
Total (95% CI) 16 17 100% 0.35[0.02,8.08]
Favours Lispro 500.02 100.1 1 Favours Regular insulin
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Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 0 (Lispro insulin), 1 (Regular insulin)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.65(P=0.51)  
Favours Lispro 500.02 100.1 1 Favours Regular insulin
 
 
Analysis 1.5.   Comparison 1 Lispro versus regular insulin (Dierent insulin types within similar
insulin regimens), Outcome 5 Birth trauma, including shoulder dystocia, nerve palsy, and fracture.
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Persson 2002 0/16 0/17   Not estimable
   
Total (95% CI) 16 17 Not estimable
Total events: 0 (Lispro insulin), 0 (Regular insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Lispro 200.05 50.2 1 Favours Regular insulin
 
 
Analysis 1.6.   Comparison 1 Lispro versus regular insulin (Dierent insulin types within
similar insulin regimens), Outcome 6 Vaginal delivery (spontaneous, ventouse, forceps).
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Persson 2002 11/16 8/17 100% 1.46[0.8,2.67]
   
Total (95% CI) 16 17 100% 1.46[0.8,2.67]
Total events: 11 (Lispro insulin), 8 (Regular insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.23(P=0.22)  
Favours Lispro 50.2 20.5 1 Favours Regular insulin
 
 
Analysis 1.7.   Comparison 1 Lispro versus regular insulin (Dierent insulin types within
similar insulin regimens), Outcome 7 Blood glucose (mmol/L) week 14 (aQer lunch).
Study or subgroup Lispro insulin Regular insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Persson 2002 16 6.2 (3.2) 17 7.3 (4.1) 100% -1.09[-3.6,1.42]
   
Total *** 16   17   100% -1.09[-3.6,1.42]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.39)  
Favours Lispro 52.5-5 -2.5 0 Favours Regular insulin
 
 
Dierent insulin types and regimens for pregnant women with pre-existing diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
48
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 1.8.   Comparison 1 Lispro versus regular insulin (Dierent insulin types within similar
insulin regimens), Outcome 8 Blood glucose (mmol/L) weeks 21, 28, and 34 combined (aQer lunch).
Study or subgroup Lispro insulin Regular insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Persson 2002 16 6.7 (2.8) 17 6.8 (3.2) 100% -0.04[-2.1,2.02]
   
Total *** 16   17   100% -0.04[-2.1,2.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
Favours Lispro 52.5-5 -2.5 0 Favours Regular insulin
 
 
Analysis 1.9.   Comparison 1 Lispro versus regular insulin (Dierent insulin types within similar insulin
regimens), Outcome 9 Postprandial increase of blood glucose (mmol/L) before week 14 (lunch).
Study or subgroup Lispro insulin Regular insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Persson 2002 16 1.1 (4.3) 17 0.1 (2.9) 100% 1[-1.52,3.52]
   
Total *** 16   17   100% 1[-1.52,3.52]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.78(P=0.44)  
Favours Lispro 52.5-5 -2.5 0 Favours Regular insulin
 
 
Analysis 1.10.   Comparison 1 Lispro versus regular insulin (Dierent insulin types within similar insulin regimens),
Outcome 10 Postprandial increase of blood glucose (mmol/L) during weeks 21, 28, and 34 combined (lunch).
Study or subgroup Lispro insulin Regular insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Persson 2002 16 0.7 (3.2) 17 0.6 (3.3) 100% 0.1[-2.12,2.32]
   
Total *** 16   17   100% 0.1[-2.12,2.32]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.09(P=0.93)  
Favours Lispro 52.5-5 -2.5 0 Favours Regular insulin
 
 
Analysis 1.11.   Comparison 1 Lispro versus regular insulin (Dierent insulin types within similar insulin
regimens), Outcome 11 Maternal hypoglycaemia and hyperglycaemia episodes requiring intervention.
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Persson 2002 0/16 2/17 100% 0.21[0.01,4.1]
   
Total (95% CI) 16 17 100% 0.21[0.01,4.1]
Total events: 0 (Lispro insulin), 2 (Regular insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.03(P=0.3)  
Favours Lispro 10000.001 100.1 1 Favours Regular insulin
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Analysis 1.12.   Comparison 1 Lispro versus regular insulin (Dierent
insulin types within similar insulin regimens), Outcome 12 Retinopathy.
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Persson 2002 2/16 2/17 100% 1.06[0.17,6.67]
   
Total (95% CI) 16 17 100% 1.06[0.17,6.67]
Total events: 2 (Lispro insulin), 2 (Regular insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.95)  
Favours Lispro 10000.001 100.1 1 Favours Regular insulin
 
 
Analysis 1.13.   Comparison 1 Lispro versus regular insulin (Dierent insulin
types within similar insulin regimens), Outcome 13 Ventouse delivery.
Study or subgroup Lispro insulin Regular insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Persson 2002 3/16 1/17 100% 3.19[0.37,27.58]
   
Total (95% CI) 16 17 100% 3.19[0.37,27.58]
Total events: 3 (Lispro insulin), 1 (Regular insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.29)  
Favours Lispro 500.02 100.1 1 Favours Regular insulin
 
 
Comparison 2.   Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal insulin (Dierent
insulin types within similar insulin regimens)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Small-for-gestational age at
delivery
1 42 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Preterm birth (< 37 weeks) 1 42 Risk Ratio (M-H, Fixed, 95% CI) 7.67 [0.42, 139.83]
3 Birthweight centile (%) 1 42 Mean Difference (IV, Fixed, 95% CI) -6.70 [-23.64, 10.24]
4 Infant length (cm) 1 42 Mean Difference (IV, Fixed, 95% CI) -3.30 [-6.74, 0.14]
5 Skinfold thickness (mm) 1 42 Mean Difference (IV, Fixed, 95% CI) -4.10 [-13.28, 5.08]
6 Body weight percentile (%) 1 42 Mean Difference (IV, Fixed, 95% CI) -6.70 [-23.74, 10.34]
7 Head circumference (cm) 1 42 Mean Difference (IV, Fixed, 95% CI) -5.10 [-9.52, -0.68]
8 Macrosomia 1 42 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 4.30]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
9 Insulin requirement during
pregnancy (U/kg/24 hour)
1 42 Mean Difference (IV, Fixed, 95% CI) -0.33 [-0.45, -0.21]
10 Birthweight (g) 1 42 Mean Difference (IV, Fixed, 95% CI) -591.0 [-1066.27,
-115.73]
11 Infant fasting C-peptide lev-
el at 3 months (pmol/mL)
1 42 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.13, -0.01]
12 Infant C-peptide level 1
hour after glucose-amino acid
challenge at 3 months (pmol/
mL)
1 42 Mean Difference (IV, Fixed, 95% CI) -0.11 [-0.19, -0.03]
13 Infant glucose fasting level
at 3 months (pmol/mL)
1 42 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.62, 0.22]
14 Infant glucose level 1 hour
after glucose-amino acid chal-
lenge at 3 months (pmol/mL)
1 42 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.04, 1.04]
15 Gestational age at delivery
(weeks)
1 42 Mean Difference (IV, Fixed, 95% CI) 0.5 [-3.70, 4.70]
16 Maternal ketonuria 1 42 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.08, 1.61]
 
 
Analysis 2.1.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Dierent insulin types within similar insulin regimens), Outcome 1 Small-for-gestational age at delivery.
Study or subgroup Human insulin Animal insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Jovanovic-Peterson 1992 0/20 0/22   Not estimable
   
Total (95% CI) 20 22 Not estimable
Total events: 0 (Human insulin), 0 (Animal insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours human insulin 1000.01 100.1 1 Favours animal insulin
 
 
Analysis 2.2.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Dierent insulin types within similar insulin regimens), Outcome 2 Preterm birth (< 37 weeks).
Study or subgroup Human insulin Animal insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Jovanovic-Peterson 1992 3/20 0/22 100% 7.67[0.42,139.83]
   
Favours Human insulin 2000.005 100.1 1 Favours Animal insulin
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Study or subgroup Human insulin Animal insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total (95% CI) 20 22 100% 7.67[0.42,139.83]
Total events: 3 (Human insulin), 0 (Animal insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.37(P=0.17)  
Favours Human insulin 2000.005 100.1 1 Favours Animal insulin
 
 
Analysis 2.3.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Dierent insulin types within similar insulin regimens), Outcome 3 Birthweight centile (%).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 47.4 (23.5) 22 54.1 (32.2) 100% -6.7[-23.64,10.24]
   
Total *** 20   22   100% -6.7[-23.64,10.24]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
Favours animal insulin 4020-40 -20 0 Favours human insulin
 
 
Analysis 2.4.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus
animal insulin (Dierent insulin types within similar insulin regimens), Outcome 4 Infant length (cm).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 47.5 (7.1) 22 50.8 (3.5) 100% -3.3[-6.74,0.14]
   
Total *** 20   22   100% -3.3[-6.74,0.14]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.88(P=0.06)  
Favours animal insulin 105-10 -5 0 Favours human insulin
 
 
Analysis 2.5.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Dierent insulin types within similar insulin regimens), Outcome 5 Skinfold thickness (mm).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 17.2 (12.8) 22 21.3 (17.4) 100% -4.1[-13.28,5.08]
   
Total *** 20   22   100% -4.1[-13.28,5.08]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
Favours animal insulin 2010-20 -10 0 Favours human insulin
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Analysis 2.6.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Dierent insulin types within similar insulin regimens), Outcome 6 Body weight percentile (%).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 47.4 (23.5) 22 54.1 (32.5) 100% -6.7[-23.74,10.34]
   
Total *** 20   22   100% -6.7[-23.74,10.34]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
Favours animal insulin 2010-20 -10 0 Favours human insulin
 
 
Analysis 2.7.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Dierent insulin types within similar insulin regimens), Outcome 7 Head circumference (cm).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 30.5 (9.9) 22 35.6 (2) 100% -5.1[-9.52,-0.68]
   
Total *** 20   22   100% -5.1[-9.52,-0.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.26(P=0.02)  
Favours animal insulin 105-10 -5 0 Favours human insulin
 
 
Analysis 2.8.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus
animal insulin (Dierent insulin types within similar insulin regimens), Outcome 8 Macrosomia.
Study or subgroup Human insulin Animal insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Jovanovic-Peterson 1992 0/20 2/22 100% 0.22[0.01,4.3]
   
Total (95% CI) 20 22 100% 0.22[0.01,4.3]
Total events: 0 (Human insulin), 2 (Animal insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
Favours Human insulin 100.1 50.2 20.5 1 Favours Animal insulin
 
 
Analysis 2.9.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid
- Humulin) versus animal insulin (Dierent insulin types within similar insulin
regimens), Outcome 9 Insulin requirement during pregnancy (U/kg/24 hour).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 1 (0.2) 22 1.3 (0.2) 100% -0.33[-0.45,-0.21]
   
Total *** 20   22   100% -0.33[-0.45,-0.21]
Heterogeneity: Not applicable  
Favours Human insulin 0.50.25-0.5 -0.25 0 Favours Animal insulin
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Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Test for overall effect: Z=5.34(P<0.0001)  
Favours Human insulin 0.50.25-0.5 -0.25 0 Favours Animal insulin
 
 
Analysis 2.10.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus
animal insulin (Dierent insulin types within similar insulin regimens), Outcome 10 Birthweight (g).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 2727 (834) 22 3318 (727) 100% -591[-1066.27,-115.73]
   
Total *** 20   22   100% -591[-1066.27,-115.73]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.44(P=0.01)  
Favours animal insulin 1000500-1000 -500 0 Favours human insulin
 
 
Analysis 2.11.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid
- Humulin) versus animal insulin (Dierent insulin types within similar insulin
regimens), Outcome 11 Infant fasting C-peptide level at 3 months (pmol/mL).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 0.2 (0.1) 22 0.3 (0.1) 100% -0.07[-0.13,-0.01]
   
Total *** 20   22   100% -0.07[-0.13,-0.01]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.15(P=0.03)  
Favours Human insulin 10.5-1 -0.5 0 Favours Animal insulin
 
 
Analysis 2.12.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin)
versus animal insulin (Dierent insulin types within similar insulin regimens), Outcome 12
Infant C-peptide level 1 hour aQer glucose-amino acid challenge at 3 months (pmol/mL).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 0.2 (0.1) 22 0.3 (0.1) 100% -0.11[-0.19,-0.03]
   
Total *** 20   22   100% -0.11[-0.19,-0.03]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.74(P=0.01)  
Favours Human insulin 0.40.2-0.4 -0.2 0 Favours Animal insulin
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Analysis 2.13.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid
- Humulin) versus animal insulin (Dierent insulin types within similar insulin
regimens), Outcome 13 Infant glucose fasting level at 3 months (pmol/mL).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 4.3 (0.7) 22 4.5 (0.7) 100% -0.2[-0.62,0.22]
   
Total *** 20   22   100% -0.2[-0.62,0.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.92(P=0.36)  
Favours Human insulin 10.5-1 -0.5 0 Favours Animal insulin
 
 
Analysis 2.14.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin)
versus animal insulin (Dierent insulin types within similar insulin regimens), Outcome
14 Infant glucose level 1 hour aQer glucose-amino acid challenge at 3 months (pmol/mL).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 5.4 (0.9) 22 4.9 (0.9) 100% 0.5[-0.04,1.04]
   
Total *** 20   22   100% 0.5[-0.04,1.04]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.8(P=0.07)  
Favours Human insulin 21-2 -1 0 Favours Animal insulin
 
 
Analysis 2.15.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus animal
insulin (Dierent insulin types within similar insulin regimens), Outcome 15 Gestational age at delivery (weeks).
Study or subgroup Human insulin Animal insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Jovanovic-Peterson 1992 20 38.6 (9.4) 22 38.1 (1.9) 100% 0.5[-3.7,4.7]
   
Total *** 20   22   100% 0.5[-3.7,4.7]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.23(P=0.82)  
Favours Human insulin 105-10 -5 0 Favours Animal insulin
 
 
Analysis 2.16.   Comparison 2 Human insulin (recombinant deoxyribonucleic acid - Humulin) versus
animal insulin (Dierent insulin types within similar insulin regimens), Outcome 16 Maternal ketonuria.
Study or subgroup Human insulin Animal insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Jovanovic-Peterson 1992 2/20 6/22 100% 0.37[0.08,1.61]
   
Total (95% CI) 20 22 100% 0.37[0.08,1.61]
Total events: 2 (Human insulin), 6 (Animal insulin)  
Favours Human insulin 50.2 20.5 1 Favours Animal insulin
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Study or subgroup Human insulin Animal insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=1.33(P=0.18)  
Favours Human insulin 50.2 20.5 1 Favours Animal insulin
 
 
Comparison 3.   Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Dierent insulin regimens
with similar insulin types used within the regimen)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Macrosomia 1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.09, 2.54]
2 Caesarean section 1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.25, 1.32]
3 Antepartum capillary glu-
cose measurement (mg/dL),
2 hours postprandial (after
lunch)
1 10218 Mean Difference (IV, Fixed, 95% CI) -11.25 [-12.55, -9.95]
4 Postpartum infection: en-
dometritis
1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.26, 1.04]
5 Use of healthcare resources
(maternal hospital days)
1 94 Mean Difference (IV, Fixed, 95% CI) -0.50 [-1.40, 0.41]
6 Birthweight (g) 1 93 Mean Difference (IV, Fixed, 95% CI) -116.56 [-391.81,
158.69]
7 Compliance score 1 49 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.87, 0.87]
 
 
Analysis 3.1.   Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin
(Dierent insulin regimens with similar insulin types used within the regimen), Outcome 1 Macrosomia.
Study or subgroup Pre-mixed
insulin
Self-mixed
insulin
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Schuster 1998 2/47 4/46 100% 0.49[0.09,2.54]
   
Total (95% CI) 47 46 100% 0.49[0.09,2.54]
Total events: 2 (Pre-mixed insulin), 4 (Self-mixed insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.4)  
Favours Pre-mix insulin 200.05 50.2 1 Favours Self-mix insulin
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Analysis 3.2.   Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Dierent
insulin regimens with similar insulin types used within the regimen), Outcome 2 Caesarean section.
Study or subgroup Pre-mixed
insulin
Self-mixed
insulin
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Schuster 1998 7/47 12/46 100% 0.57[0.25,1.32]
   
Total (95% CI) 47 46 100% 0.57[0.25,1.32]
Total events: 7 (Pre-mixed insulin), 12 (Self-mixed insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.31(P=0.19)  
Favours Pre-mix insulin 200.05 50.2 1 Favours Self-mix insulin
 
 
Analysis 3.3.   Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose
insulin (Dierent insulin regimens with similar insulin types used within the regimen), Outcome
3 Antepartum capillary glucose measurement (mg/dL), 2 hours postprandial (aQer lunch).
Study or subgroup Pre-mixed insulin Self-mixed insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Schuster 1998 5698 131.8 (28.4) 4520 143 (36.7) 100% -11.25[-12.55,-9.95]
   
Total *** 5698   4520   100% -11.25[-12.55,-9.95]
Heterogeneity: Not applicable  
Test for overall effect: Z=16.96(P<0.0001)  
Favours Pre-mix insulin 2010-20 -10 0 Favours Self-mix insulin
 
 
Analysis 3.4.   Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Dierent insulin
regimens with similar insulin types used within the regimen), Outcome 4 Postpartum infection: endometritis.
Study or subgroup Pre-mixed
insulin
Self-mixed
insulin
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Schuster 1998 9/47 17/46 100% 0.52[0.26,1.04]
   
Total (95% CI) 47 46 100% 0.52[0.26,1.04]
Total events: 9 (Pre-mixed insulin), 17 (Self-mixed insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.85(P=0.06)  
Favours Pre-mix insulin 50.2 20.5 1 Favours Self-mix insulin
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Analysis 3.5.   Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed
split dose insulin (Dierent insulin regimens with similar insulin types used within
the regimen), Outcome 5 Use of healthcare resources (maternal hospital days).
Study or subgroup Pre-mixed insulin Self-mixed insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Schuster 1998 47 3.9 (2) 47 4.4 (2.5) 100% -0.5[-1.4,0.41]
   
Total *** 47   47   100% -0.5[-1.4,0.41]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.08(P=0.28)  
Favours Pre-mix insulin 105-10 -5 0 Favours Self-mix insulin
 
 
Analysis 3.6.   Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin
(Dierent insulin regimens with similar insulin types used within the regimen), Outcome 6 Birthweight (g).
Study or subgroup Pre-mixed insulin Self-mixed insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Schuster 1998 47 3063.8
(732.1)
46 3180.3
(618.6)
100% -116.56[-391.81,158.69]
   
Total *** 47   46   100% -116.56[-391.81,158.69]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.83(P=0.41)  
Favours Self-mix insulin 1000500-1000 -500 0 Favours Pre-mix insulin
 
 
Analysis 3.7.   Comparison 3 Pre-mixed insulin (70 NPH/30 REG) versus self-mixed split dose insulin (Dierent
insulin regimens with similar insulin types used within the regimen), Outcome 7 Compliance score.
Study or subgroup Pre-mixed insulin Self-mixed insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Schuster 1998 24 3 (1.4) 25 3 (1.7) 100% 0[-0.87,0.87]
   
Total *** 24   25   100% 0[-0.87,0.87]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Self-mix insulin 21-2 -1 0 Favours Pre-mix insulin
 
 
Comparison 4.   Insulin injected with a Novolin pen versus insulin injected with a needle (syringe) (Dierent insulin
regimens with similar insulin types used within the regimen)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Macrosomia 1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.03, 1.76]
2 Caesarean section 1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.15, 0.97]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 Antepartum capillary glu-
cose measurement (mg/dL)
2 hours postprandial (after
lunch)
1 10218 Mean Difference (IV, Fixed, 95% CI) -7.23 [-8.51, -5.95]
4 Postpartum infection: en-
dometritis
1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.28, 1.14]
5 Use of healthcare resources
(maternal hospital days)
1 93 Mean Difference (IV, Fixed, 95% CI) -0.56 [-1.45, 0.33]
6 Birthweight (g) 1 93 Mean Difference (IV, Fixed, 95% CI) -162.36 [-438.25,
113.53]
7 Compliance score 1 93 Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.83, 0.41]
 
 
Analysis 4.1.   Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe)
(Dierent insulin regimens with similar insulin types used within the regimen), Outcome 1 Macrosomia.
Study or subgroup Novolin Pen Needle/Syringe Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Schuster 1998 1/45 5/48 100% 0.21[0.03,1.76]
   
Total (95% CI) 45 48 100% 0.21[0.03,1.76]
Total events: 1 (Novolin Pen), 5 (Needle/Syringe)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.44(P=0.15)  
Favours Pen 500.02 100.1 1 Favours Syringe
 
 
Analysis 4.2.   Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe)
(Dierent insulin regimens with similar insulin types used within the regimen), Outcome 2 Caesarean section.
Study or subgroup Novolin Pen Needle/Syringe Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Schuster 1998 5/45 14/48 100% 0.38[0.15,0.97]
   
Total (95% CI) 45 48 100% 0.38[0.15,0.97]
Total events: 5 (Novolin Pen), 14 (Needle/Syringe)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.02(P=0.04)  
Favours Pen 50.2 20.5 1 Favours Syringe
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Analysis 4.3.   Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a
needle (syringe) (Dierent insulin regimens with similar insulin types used within the regimen),
Outcome 3 Antepartum capillary glucose measurement (mg/dL) 2 hours postprandial (aQer lunch).
Study or subgroup Novolin Pen Needle/Syringe Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Schuster 1998 5425 133.4 (29.8) 4793 140.6 (35.5) 100% -7.23[-8.51,-5.95]
   
Total *** 5425   4793   100% -7.23[-8.51,-5.95]
Heterogeneity: Not applicable  
Test for overall effect: Z=11.05(P<0.0001)  
Favours Pen 105-10 -5 0 Favours Syringe
 
 
Analysis 4.4.   Comparison 4 Insulin injected with a Novolin pen versus insulin
injected with a needle (syringe) (Dierent insulin regimens with similar insulin
types used within the regimen), Outcome 4 Postpartum infection: endometritis.
Study or subgroup Novolin Pen Needle/Syringe Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Schuster 1998 9/45 17/48 100% 0.56[0.28,1.14]
   
Total (95% CI) 45 48 100% 0.56[0.28,1.14]
Total events: 9 (Novolin Pen), 17 (Needle/Syringe)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.6(P=0.11)  
Favours Pen 50.2 20.5 1 Favours Syringe
 
 
Analysis 4.5.   Comparison 4 Insulin injected with a Novolin pen versus insulin injected
with a needle (syringe) (Dierent insulin regimens with similar insulin types used
within the regimen), Outcome 5 Use of healthcare resources (maternal hospital days).
Study or subgroup Novolin Pen Needle/Syringe Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Schuster 1998 45 3.8 (1.8) 48 4.4 (2.5) 100% -0.56[-1.45,0.33]
   
Total *** 45   48   100% -0.56[-1.45,0.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.23(P=0.22)  
Favours Pen 52.5-5 -2.5 0 Favours Syringe
 
 
Analysis 4.6.   Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe)
(Dierent insulin regimens with similar insulin types used within the regimen), Outcome 6 Birthweight (g).
Study or subgroup Novolin Pen Needle/Syringe Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Schuster 1998 45 3037.6
(713.4)
48 3200
(638.9)
100% -162.36[-438.25,113.53]
Favours Syringe 500250-500 -250 0 Favours Pen
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Study or subgroup Novolin Pen Needle/Syringe Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
   
Total *** 45   48   100% -162.36[-438.25,113.53]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.15(P=0.25)  
Favours Syringe 500250-500 -250 0 Favours Pen
 
 
Analysis 4.7.   Comparison 4 Insulin injected with a Novolin pen versus insulin injected with a needle (syringe)
(Dierent insulin regimens with similar insulin types used within the regimen), Outcome 7 Compliance score.
Study or subgroup Novolin Pen Needle/Syringe Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Schuster 1998 45 2.8 (1.5) 48 3 (1.5) 100% -0.21[-0.83,0.41]
   
Total *** 45   48   100% -0.21[-0.83,0.41]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.66(P=0.51)  
Favours Syringe 42-4 -2 0 Favours Pen
 
 
Comparison 5.   Insulin Aspart + NPH insulin versus Human insulin + NPH insulin (Dierent insulin types within
similar insulin regimens)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 A1c (%) third trimester visit 1 223 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.28, 0.08]
2 Average plasma glucose (mmol/L)
third trimester visit
1 223 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.53, 0.13]
3 Maternal hypoglycaemic episodes 1 223 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.99, 1.14]
 
 
Analysis 5.1.   Comparison 5 Insulin Aspart + NPH insulin versus Human insulin + NPH insulin
(Dierent insulin types within similar insulin regimens), Outcome 1 A1c (%) third trimester visit.
Study or subgroup Aspart insulin Human insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Mathiesen 2007 113 6 (0.7) 110 6.1 (0.7) 100% -0.1[-0.28,0.08]
   
Total *** 113   110   100% -0.1[-0.28,0.08]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.07(P=0.29)  
Favours insulin Aspart 10.5-1 -0.5 0 Favours Human insulin
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Analysis 5.2.   Comparison 5 Insulin Aspart + NPH insulin versus Human insulin + NPH insulin (Dierent insulin
types within similar insulin regimens), Outcome 2 Average plasma glucose (mmol/L) third trimester visit.
Study or subgroup Aspart insulin Human insulin Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Mathiesen 2007 113 6.2 (1.2) 110 6.4 (1.3) 100% -0.2[-0.53,0.13]
   
Total *** 113   110   100% -0.2[-0.53,0.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.19(P=0.23)  
Favours Aspart insulin 21-2 -1 0 Favours Human insulin
 
 
Analysis 5.3.   Comparison 5 Insulin Aspart + NPH insulin versus Human insulin + NPH insulin (Dierent
insulin types within similar insulin regimens), Outcome 3 Maternal hypoglycaemic episodes.
Study or subgroup Aspart insulin Human insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Mathiesen 2007 108/113 99/110 100% 1.06[0.99,1.14]
   
Total (95% CI) 113 110 100% 1.06[0.99,1.14]
Total events: 108 (Aspart insulin), 99 (Human insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.6(P=0.11)  
Favours insulin Aspart 20.5 1.50.7 1 Favours Human insulin
 
 
Comparison 6.   Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin Aspart (Dierent
insulin types within similar insulin regimens)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Major congenital malformation 1 162 Risk Ratio (M-H, Fixed, 95% CI) 3.15 [0.33, 29.67]
2 Major congenital malformation 1 162 Risk Ratio (M-H, Fixed, 95% CI) 2.10 [0.19, 22.72]
3 Minor congenital malformation 1 162 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.47]
4 Minor congenital malformation 1 162 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.22, 5.05]
 
 
Analysis 6.1.   Comparison 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin
Aspart (Dierent insulin types within similar insulin regimens), Outcome 1 Major congenital malformation.
Study or subgroup Detemir insulin NPH insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Mathiesen 2012 3/79 1/83 100% 3.15[0.33,29.67]
   
Favours insulin Detemir 10000.001 100.1 1 Favours NPH
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Study or subgroup Detemir insulin NPH insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total (95% CI) 79 83 100% 3.15[0.33,29.67]
Total events: 3 (Detemir insulin), 1 (NPH insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
Favours insulin Detemir 10000.001 100.1 1 Favours NPH
 
 
Analysis 6.2.   Comparison 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin
Aspart (Dierent insulin types within similar insulin regimens), Outcome 2 Major congenital malformation.
Study or subgroup Detemir insulin NPH insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Mathiesen 2012 2/79 1/83 100% 2.1[0.19,22.72]
   
Total (95% CI) 79 83 100% 2.1[0.19,22.72]
Total events: 2 (Detemir insulin), 1 (NPH insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
Favours insulin Detemir 1000.01 100.1 1 Favours NPH
 
 
Analysis 6.3.   Comparison 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin
Aspart (Dierent insulin types within similar insulin regimens), Outcome 3 Minor congenital malformation.
Study or subgroup Detemir insulin NPH insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Mathiesen 2012 0/79 1/83 100% 0.35[0.01,8.47]
   
Total (95% CI) 79 83 100% 0.35[0.01,8.47]
Total events: 0 (Detemir insulin), 1 (NPH insulin)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.65(P=0.52)  
Favours insulin Detemir 1000.01 100.1 1 Favours NPH
 
 
Analysis 6.4.   Comparison 6 Insulin Detemir + prandial insulin Aspart versus NPH insulin + prandial insulin
Aspart (Dierent insulin types within similar insulin regimens), Outcome 4 Minor congenital malformation.
Study or subgroup Detemir insulin NPH insulin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Mathiesen 2012 3/79 3/83 100% 1.05[0.22,5.05]
   
Total (95% CI) 79 83 100% 1.05[0.22,5.05]
Total events: 3 (Detemir insulin), 3 (NPH insulin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.95)  
Favours insulin Detemir 1000.01 100.1 1 Favours NPH
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A P P E N D I C E S
Appendix 1. Search terms for ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform
type 1 diabetes AND pregnancy
type 2 diabetes AND pregnancy
insulin AND diabetes AND pregnancy
C O N T R I B U T I O N S   O F   A U T H O R S
All six review authors were involved in the development of this review. Sinéad O'Neill co-ordinated and drafted the review with the help
of Helen West, and is the guarantor of the review. Louise Kenny, Rebecca Smyth, and Patricia Kearney assisted in the conception of the
review, and offered a clinical perspective. Ali Khashan provided statistical advice, as well as general advice on the review. Paul Beirne
assisted with securing fellowship funding, and provided detailed comments on the protocol, but was not involved in the full review.
D E C L A R A T I O N S   O F   I N T E R E S T
SON: received support from a Health Research Board Cochrane Fellowship in order to prepare this review.
AK: none known.
LK: is As Director of the Irish Centre for Fetal and Neonatal Translational Research, and as such, has numerous grant applications under
review at any given time. She has been paid by Alere to give invited symposia on a proprietary screening test for preeclampsia. She is the
editor of Te Teachers and received royalties from the publishers. LK is also a limited share holder in Metabolomic Diagnostics, an SME who
have licensed technology she has developed pertaining to the screening of preeclampsia.
HW: Helen West is paid to work on Cochrane reviews by a grant to Cochrane Pregnancy and Childbirth. The views and opinions expressed
therein are those of the authors, and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department
of Health.
RS: none known.
PK: none known.
S O U R C E S   O F   S U P P O R T
Internal sources• The Irish Centre for Fetal and Neonatal Translational Research (INFANT), University College Cork (UCC), Ireland.
LK is a Science Foundation Ireland (SFI) Principal Investigator (08/IN/.1/B2083) and the Director of the SFI funded centre INFANT (12/
RC/2272)• University College Cork (UCC), Ireland.
PB, SON, AK, and LK are employees of UCC and receive support from the University in the form of a salary.• Cochrane Pregnancy and Childbirth Group, Department of Women's and Children's Health, The University of Liverpool, Liverpool, UK.
External sources• Health Research Board (HRB), Ireland.
SON is the recipient of a full Cochrane Fellowship (Grant no: CTF-2014-884) from the HRB, Ireland• NIHR Cochrane Programme Grant Project: 13/89/05 – Pregnancy and childbirth systematic reviews to support clinical guidelines, UK.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
1. HW has been added as an author.
2. We added additional outcomes and labelled these as 'not prespecified outcomes'. For infants, these included: birthweight (g); infant
fasting C-peptide level at three months (pmol/mL); infant C-peptide level one hour after glucose-amino acid challenge at three months
(pmol/mL)); infant fasting glucose level at three months (pmol/mL); infant glucose level one hour after glucose-amino acid challenge
Dierent insulin types and regimens for pregnant women with pre-existing diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
64
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
at three months (pmol/mL), and gestational age at delivery. Additional maternal outcomes included: ventouse delivery; maternal ke-
tonuria, and a maternal compliance with treatment score (1 = best, 5 = worst compliance).
3. We have reworded other outcomes to be in line with the list of core outcomes for diabetes in pregnancy (use of healthcare resources now
includes maternal hospital days, pre-eclampsia includes pregnancy-induced hypertension, neonatal adiposity includes body weight
percentile).
4. SON and HW performed the screening for eligibility, data extraction, and risk of bias for the included studies
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Diabetes Mellitus, Type 1  [*drug therapy];  Diabetes Mellitus, Type 2  [*drug therapy];  Hypoglycemic Agents  [administration & dosage]
 [*therapeutic use];  Insulin  [administration & dosage]  [*therapeutic use];  Insulin Aspart  [therapeutic use];  Insulin Detemir  [therapeutic
use];  Insulin Lispro  [therapeutic use];  Pregnancy Complications  [*drug therapy];  Pregnancy in Diabetics  [*drug therapy]
MeSH check words
Female; Humans; Pregnancy
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